EP1315490B1 - A method for treating allergies using substituted pyrazoles - Google Patents
A method for treating allergies using substituted pyrazoles Download PDFInfo
- Publication number
- EP1315490B1 EP1315490B1 EP01968461A EP01968461A EP1315490B1 EP 1315490 B1 EP1315490 B1 EP 1315490B1 EP 01968461 A EP01968461 A EP 01968461A EP 01968461 A EP01968461 A EP 01968461A EP 1315490 B1 EP1315490 B1 EP 1315490B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- phenyl
- alkyl
- pyridin
- piperidin
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract description 12
- 150000003217 pyrazoles Chemical class 0.000 title abstract description 5
- 206010020751 Hypersensitivity Diseases 0.000 title description 13
- 230000007815 allergy Effects 0.000 title description 11
- 206010027654 Allergic conditions Diseases 0.000 claims abstract description 20
- -1 cyano, amino, hydroxy Chemical group 0.000 claims description 247
- 125000000217 alkyl group Chemical group 0.000 claims description 123
- 229910052739 hydrogen Inorganic materials 0.000 claims description 106
- 239000001257 hydrogen Substances 0.000 claims description 104
- 150000001875 compounds Chemical class 0.000 claims description 102
- 125000000623 heterocyclic group Chemical group 0.000 claims description 98
- 150000002431 hydrogen Chemical class 0.000 claims description 72
- 125000003342 alkenyl group Chemical group 0.000 claims description 68
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 60
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 57
- 125000002252 acyl group Chemical group 0.000 claims description 49
- 125000003118 aryl group Chemical group 0.000 claims description 49
- 125000003545 alkoxy group Chemical group 0.000 claims description 47
- 229920006395 saturated elastomer Polymers 0.000 claims description 46
- 229910052736 halogen Inorganic materials 0.000 claims description 43
- 150000002367 halogens Chemical class 0.000 claims description 41
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 37
- 125000001424 substituent group Chemical group 0.000 claims description 35
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 34
- 125000002947 alkylene group Chemical group 0.000 claims description 32
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 32
- 229910003844 NSO2 Inorganic materials 0.000 claims description 31
- 150000001408 amides Chemical class 0.000 claims description 30
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 125000003435 aroyl group Chemical group 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 17
- 150000002148 esters Chemical class 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 229910021481 rutherfordium Inorganic materials 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000002950 monocyclic group Chemical group 0.000 claims description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 9
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 9
- 229910052701 rubidium Inorganic materials 0.000 claims description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- 125000002837 carbocyclic group Chemical group 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 229910052702 rhenium Inorganic materials 0.000 claims description 8
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 7
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 7
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 7
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 7
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 6
- 229910052705 radium Inorganic materials 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 5
- 125000001188 haloalkyl group Chemical group 0.000 claims description 5
- 125000004970 halomethyl group Chemical group 0.000 claims description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
- 229910052703 rhodium Inorganic materials 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- ZXKGWRPXSJPOKF-UHFFFAOYSA-N 1-[1-[3-[4-(5-chloro-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-hydroxypropyl]-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)C=3OC4=CC=C(Cl)C=C4N=3)=C1C=2C1=CC=C(C(F)(F)F)C=C1 ZXKGWRPXSJPOKF-UHFFFAOYSA-N 0.000 claims description 4
- RPDHUDLDZNBYCR-UHFFFAOYSA-N 1-[3-[4-(3-methyl-2-oxobenzimidazol-1-yl)piperidin-1-yl]propyl]-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-sulfonamide Chemical compound O=C1N(C)C2=CC=CC=C2N1C(CC1)CCN1CCCN(C=1CCN(CC=11)S(N)(=O)=O)N=C1C1=CC=C(C(F)(F)F)C=C1 RPDHUDLDZNBYCR-UHFFFAOYSA-N 0.000 claims description 4
- YYOUOFYFDWPNFX-UHFFFAOYSA-N 2-[3-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-2-oxobenzimidazol-1-yl]acetonitrile Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C(N(CC#N)C4=CC=CC=C43)=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 YYOUOFYFDWPNFX-UHFFFAOYSA-N 0.000 claims description 4
- KMQBHSPGLHHBDJ-UHFFFAOYSA-N 3-[1-[3-[5-acetyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1N(C(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C(NC4=CC=CC=C43)=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 KMQBHSPGLHHBDJ-UHFFFAOYSA-N 0.000 claims description 4
- NOLNAXDAJMZSDZ-UHFFFAOYSA-N 4-[1-[2-hydroxy-3-[4-pyrazin-2-yl-3-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]propyl]piperidin-4-yl]-1,4-benzoxazin-3-one Chemical compound C1CC(N2C3=CC=CC=C3OCC2=O)CCN1CC(O)CN(N=1)C=C(C=2N=CC=NC=2)C=1C1=CC=C(C(F)(F)F)C=C1 NOLNAXDAJMZSDZ-UHFFFAOYSA-N 0.000 claims description 4
- AMSFCNUCSFWCJW-UHFFFAOYSA-N 4-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-1,4-benzoxazin-3-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C4=CC=CC=C4OCC3=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 AMSFCNUCSFWCJW-UHFFFAOYSA-N 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- AMCNPPFEXBCLKP-QHCPKHFHSA-N 1-[1-[(2s)-2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-3-methylbenzimidazol-2-one Chemical compound C([C@@H](O)CN1CCC(CC1)N1C2=CC=CC=C2N(C1=O)C)N(C=1CCN(CC=11)S(C)(=O)=O)N=C1C1=CC=C(C(F)(F)F)C=C1 AMCNPPFEXBCLKP-QHCPKHFHSA-N 0.000 claims description 3
- VBIFOHHKLKGTEY-UHFFFAOYSA-N 1-[1-[2-hydroxy-3-[4-[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]piperidin-1-yl]propyl]-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)C=3SC4=CC=C(C=C4N=3)C(F)(F)F)=C1C=2C1=CC=C(C(F)(F)F)C=C1 VBIFOHHKLKGTEY-UHFFFAOYSA-N 0.000 claims description 3
- CWRHAHWUQWSODC-UHFFFAOYSA-N 1-[1-[3-[4-(1,2-benzoxazol-3-yloxy)piperidin-1-yl]-2-hydroxypropyl]-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)OC=3C4=CC=CC=C4ON=3)=C1C=2C1=CC=C(C(F)(F)F)C=C1 CWRHAHWUQWSODC-UHFFFAOYSA-N 0.000 claims description 3
- QLHUEYGXTMIBFL-UHFFFAOYSA-N 1-[1-[3-[4-(1,3-benzothiazol-2-ylamino)piperidin-1-yl]-2-hydroxypropyl]-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)NC=3SC4=CC=CC=C4N=3)=C1C=2C1=CC=C(C(F)(F)F)C=C1 QLHUEYGXTMIBFL-UHFFFAOYSA-N 0.000 claims description 3
- ZOTAYVJUYBDAHN-UHFFFAOYSA-N 1-[1-[3-[4-(3,5-dichloropyridin-4-yl)oxypiperidin-1-yl]-2-hydroxypropyl]-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC2=C1C(C=1C=CC(=CC=1)C(F)(F)F)=NN2CC(O)CN(CC1)CCC1OC1=C(Cl)C=NC=C1Cl ZOTAYVJUYBDAHN-UHFFFAOYSA-N 0.000 claims description 3
- FLIVFIJZPUHWGN-UHFFFAOYSA-N 1-[1-[3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-3,4-dihydroquinazolin-2-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CCCN3CCC(CC3)N3C4=CC=CC=C4CNC3=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 FLIVFIJZPUHWGN-UHFFFAOYSA-N 0.000 claims description 3
- PQAKJEOGMDKODZ-UHFFFAOYSA-N 1-[1-[3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-3h-indol-2-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CCCN3CCC(CC3)N3C4=CC=CC=C4CC3=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 PQAKJEOGMDKODZ-UHFFFAOYSA-N 0.000 claims description 3
- PYIPKNAIIKVGRR-UHFFFAOYSA-N 1-[3-(4-chloro-3-methylphenyl)-1-[3-[4-(2,3-dihydroindol-1-yl)piperidin-1-yl]-2-hydroxypropyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C4=CC=CC=C4CC3)=C1C=2C1=CC=C(Cl)C(C)=C1 PYIPKNAIIKVGRR-UHFFFAOYSA-N 0.000 claims description 3
- IAUKUNDXBMIFRM-UHFFFAOYSA-N 1-[3-(4-chloro-3-methylphenyl)-1-[3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]propyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC2=C1C(C=1C=C(C)C(Cl)=CC=1)=NN2CCCN(CC1)CCC1OC1=CC=C(Cl)C(Cl)=C1 IAUKUNDXBMIFRM-UHFFFAOYSA-N 0.000 claims description 3
- YIWJQRGLHKAHLP-UHFFFAOYSA-N 1-[3-[4-(6-chloro-3-methyl-2-oxobenzimidazol-1-yl)piperidin-1-yl]propyl]-3-(3,4-dichlorophenyl)-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carboxamide Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2N1C(CC1)CCN1CCCN(C=1CCN(CC=11)C(N)=O)N=C1C1=CC=C(Cl)C(Cl)=C1 YIWJQRGLHKAHLP-UHFFFAOYSA-N 0.000 claims description 3
- XLBFTGSAZVJCHG-UHFFFAOYSA-N 1-[4-(6-chloro-2,2-dioxo-3,4-dihydro-2$l^{6},1,3-benzothiadiazin-1-yl)piperidin-1-yl]-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3S(NCC4=CC(Cl)=CC=C43)(=O)=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 XLBFTGSAZVJCHG-UHFFFAOYSA-N 0.000 claims description 3
- YJRZPJFONNBCCL-UHFFFAOYSA-N 1-[4-(6-chloroindol-1-yl)piperidin-1-yl]-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C4=CC(Cl)=CC=C4C=C3)=C1C=2C1=CC=C(C(F)(F)F)C=C1 YJRZPJFONNBCCL-UHFFFAOYSA-N 0.000 claims description 3
- YIOQMSOCBMJLFI-UHFFFAOYSA-N 2-[[1-[3-[5-acetyl-3-(4-chlorophenyl)-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]amino]benzonitrile Chemical compound C1N(C(=O)C)CCC2=C1C(C=1C=CC(Cl)=CC=1)=NN2CC(O)CN(CC1)CCC1NC1=CC=CC=C1C#N YIOQMSOCBMJLFI-UHFFFAOYSA-N 0.000 claims description 3
- QTGJYPWHCIKBHE-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-1-[3-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]propyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carboxamide Chemical compound C1N(C(=O)N)CCC(N(N=2)CCCN3CCC(CC3)N3C(NC4=CC=CC=C43)=O)=C1C=2C1=CC=C(Cl)C(Cl)=C1 QTGJYPWHCIKBHE-UHFFFAOYSA-N 0.000 claims description 3
- FHCDFGIDYPFSFW-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-1-[3-[4-(3-methyl-2-oxobenzimidazol-1-yl)piperidin-1-yl]propyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carboxamide Chemical compound O=C1N(C)C2=CC=CC=C2N1C(CC1)CCN1CCCN(C=1CCN(CC=11)C(N)=O)N=C1C1=CC=C(Cl)C(Cl)=C1 FHCDFGIDYPFSFW-UHFFFAOYSA-N 0.000 claims description 3
- GHURAXYCUPZFMT-UHFFFAOYSA-N 3-(4-bromophenyl)-1-[2-hydroxy-3-[4-(5-methoxy-2-oxo-1h-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl]propyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carboxamide Chemical compound C12=NC(OC)=CC=C2NC(=O)N1C(CC1)CCN1CC(O)CN(C=1CCN(CC=11)C(N)=O)N=C1C1=CC=C(Br)C=C1 GHURAXYCUPZFMT-UHFFFAOYSA-N 0.000 claims description 3
- SVNPCROCRJHPKS-QHCPKHFHSA-N 3-[1-[(2s)-3-[5-acetyl-3-(4-chloro-3-methylphenyl)-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]-5-chloro-1h-benzimidazol-2-one Chemical compound C1N(C(=O)C)CCC(N(N=2)C[C@@H](O)CN3CCC(CC3)N3C(NC4=CC=C(Cl)C=C43)=O)=C1C=2C1=CC=C(Cl)C(C)=C1 SVNPCROCRJHPKS-QHCPKHFHSA-N 0.000 claims description 3
- UGLKTMABKZLPJO-UHFFFAOYSA-N 3-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-1,5-dimethylbenzimidazol-2-one Chemical compound C12=CC(C)=CC=C2N(C)C(=O)N1C(CC1)CCN1CC(O)CN(C=1CCN(CC=11)S(C)(=O)=O)N=C1C1=CC=C(C(F)(F)F)C=C1 UGLKTMABKZLPJO-UHFFFAOYSA-N 0.000 claims description 3
- SAUHEEDSRFEWQU-UHFFFAOYSA-N 3-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-5-methoxy-1-methylimidazo[4,5-b]pyridin-2-one Chemical compound C12=NC(OC)=CC=C2N(C)C(=O)N1C(CC1)CCN1CC(O)CN(C=1CCN(CC=11)S(C)(=O)=O)N=C1C1=CC=C(C(F)(F)F)C=C1 SAUHEEDSRFEWQU-UHFFFAOYSA-N 0.000 claims description 3
- NXNBMJMGFHVRNG-UHFFFAOYSA-N 3-[1-[3-[3-(4-bromophenyl)-5-methylsulfonyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]-5-chloro-1h-benzimidazol-2-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C(NC4=CC=C(Cl)C=C43)=O)=C1C=2C1=CC=C(Br)C=C1 NXNBMJMGFHVRNG-UHFFFAOYSA-N 0.000 claims description 3
- VJJZRYOZUHLYOL-UHFFFAOYSA-N 3-[1-[3-[3-(4-bromophenyl)-5-methylsulfonyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]-5-methoxy-1h-imidazo[4,5-b]pyridin-2-one Chemical compound C12=NC(OC)=CC=C2NC(=O)N1C(CC1)CCN1CC(O)CN(C=1CCN(CC=11)S(C)(=O)=O)N=C1C1=CC=C(Br)C=C1 VJJZRYOZUHLYOL-UHFFFAOYSA-N 0.000 claims description 3
- MTMAHYOKSPDTMJ-UHFFFAOYSA-N 3-[1-[3-[5-acetyl-3-(4-bromophenyl)-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]-1,3-benzoxazol-2-one Chemical compound C1N(C(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C(OC4=CC=CC=C43)=O)=C1C=2C1=CC=C(Br)C=C1 MTMAHYOKSPDTMJ-UHFFFAOYSA-N 0.000 claims description 3
- ANFWDRBSMJXUMQ-UHFFFAOYSA-N 4-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C4=NC=CC=C4OCC3=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 ANFWDRBSMJXUMQ-UHFFFAOYSA-N 0.000 claims description 3
- OMDGGXZLVWQNQJ-UHFFFAOYSA-N 4-[1-[3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-1,4-benzoxazin-3-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CCCN3CCC(CC3)N3C4=CC=CC=C4OCC3=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 OMDGGXZLVWQNQJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 3
- GSNMMRBJVRIWNW-QHCPKHFHSA-N 5-(dimethylamino)-3-[1-[(2s)-2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-1-methylimidazo[4,5-b]pyridin-2-one Chemical compound C([C@@H](O)CN1CCC(CC1)N1C(=O)N(C)C2=CC=C(N=C21)N(C)C)N(C=1CCN(CC=11)S(C)(=O)=O)N=C1C1=CC=C(C(F)(F)F)C=C1 GSNMMRBJVRIWNW-QHCPKHFHSA-N 0.000 claims description 3
- GOLVHZSOSHXYKB-UHFFFAOYSA-N 5-chloro-1-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-3h-indol-2-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C4=CC=C(Cl)C=C4CC3=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 GOLVHZSOSHXYKB-UHFFFAOYSA-N 0.000 claims description 3
- YXDINUJTWVWARA-UHFFFAOYSA-N 5-chloro-3-[1-[2-hydroxy-3-[4-pyridin-4-yl-3-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]propyl]piperidin-4-yl]-1-methylbenzimidazol-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2N1C(CC1)CCN1CC(O)CN(N=1)C=C(C=2C=CN=CC=2)C=1C1=CC=C(C(F)(F)F)C=C1 YXDINUJTWVWARA-UHFFFAOYSA-N 0.000 claims description 3
- QXIOGFFGXFJNOS-UHFFFAOYSA-N 5-chloro-3-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-1-methylbenzimidazol-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2N1C(CC1)CCN1CC(O)CN(C=1CCN(CC=11)S(C)(=O)=O)N=C1C1=CC=C(C(F)(F)F)C=C1 QXIOGFFGXFJNOS-UHFFFAOYSA-N 0.000 claims description 3
- DTHYSTMEINIJIK-UHFFFAOYSA-N 5-chloro-3-[1-[3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CCCN3CCC(CC3)N3C(NC4=CC=C(Cl)C=C43)=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 DTHYSTMEINIJIK-UHFFFAOYSA-N 0.000 claims description 3
- FGUVGHPZGGMLJY-UHFFFAOYSA-N 6-chloro-1-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-3,4-dihydroquinolin-2-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C4=CC=C(Cl)C=C4CCC3=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 FGUVGHPZGGMLJY-UHFFFAOYSA-N 0.000 claims description 3
- YOEQCVQKYFHFEI-UHFFFAOYSA-N 6-chloro-1-[1-[3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-3h-indol-2-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CCCN3CCC(CC3)N3C4=CC(Cl)=CC=C4CC3=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 YOEQCVQKYFHFEI-UHFFFAOYSA-N 0.000 claims description 3
- PXKDEJBONDAVII-UHFFFAOYSA-N 6-chloro-4-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-1,4-benzoxazin-3-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C4=CC(Cl)=CC=C4OCC3=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 PXKDEJBONDAVII-UHFFFAOYSA-N 0.000 claims description 3
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 2
- KJDYMUXDHOISCN-UHFFFAOYSA-N 1-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-3,4-dihydroquinolin-2-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C4=CC=CC=C4CCC3=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 KJDYMUXDHOISCN-UHFFFAOYSA-N 0.000 claims description 2
- IQSYKFVEYHUMIJ-UHFFFAOYSA-N 1-[1-[3-[5-acetyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]-3-(2-morpholin-4-ylethyl)benzimidazol-2-one Chemical compound C1N(C(=O)C)CCC2=C1C(C=1C=CC(=CC=1)C(F)(F)F)=NN2CC(O)CN(CC1)CCC1N(C1=O)C2=CC=CC=C2N1CCN1CCOCC1 IQSYKFVEYHUMIJ-UHFFFAOYSA-N 0.000 claims description 2
- XECJQIFAFCKQAR-UHFFFAOYSA-N 1-[1-[3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]benzotriazole Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CCCN3CCC(CC3)N3C4=CC=CC=C4N=N3)=C1C=2C1=CC=C(C(F)(F)F)C=C1 XECJQIFAFCKQAR-UHFFFAOYSA-N 0.000 claims description 2
- DSXTVHUNSQOTDH-UHFFFAOYSA-N 1-[3-(4-chloro-3-methylphenyl)-1-[3-[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-2-hydroxypropyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC2=C1C(C=1C=C(C)C(Cl)=CC=1)=NN2CC(O)CN(CC1)CCC1C(ON=1)=NC=1C1=CC=C(Cl)C=C1 DSXTVHUNSQOTDH-UHFFFAOYSA-N 0.000 claims description 2
- UBASNBVIPXYMIM-UHFFFAOYSA-N 3-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-1h-imidazo[4,5-b]pyridin-2-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C(NC4=CC=CN=C43)=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 UBASNBVIPXYMIM-UHFFFAOYSA-N 0.000 claims description 2
- YMQLLQKQRQQXHP-UHFFFAOYSA-N 3-[1-[3-[5-acetyl-3-(4-bromophenyl)-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]-6-methoxy-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(OC)=CC=C2N1C(CC1)CCN1CC(O)CN(C=1CCN(CC=11)C(C)=O)N=C1C1=CC=C(Br)C=C1 YMQLLQKQRQQXHP-UHFFFAOYSA-N 0.000 claims description 2
- IUGKAAXMZDREEY-UHFFFAOYSA-N 5-(dimethylamino)-3-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-1h-imidazo[4,5-b]pyridin-2-one Chemical compound C12=NC(N(C)C)=CC=C2NC(=O)N1C(CC1)CCN1CC(O)CN(C=1CCN(CC=11)S(C)(=O)=O)N=C1C1=CC=C(C(F)(F)F)C=C1 IUGKAAXMZDREEY-UHFFFAOYSA-N 0.000 claims description 2
- NVAHQQYCEWEDKM-UHFFFAOYSA-N 5-chloro-1-methyl-3-[1-[3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]benzimidazol-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2N1C(CC1)CCN1CCCN(C=1CCN(CC=11)S(C)(=O)=O)N=C1C1=CC=C(C(F)(F)F)C=C1 NVAHQQYCEWEDKM-UHFFFAOYSA-N 0.000 claims description 2
- UCQLUWCPLPDLFX-UHFFFAOYSA-N 5-chloro-3-[1-[3-[3-(4-chloro-3-methylphenyl)-5-methylsulfonyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=C(Cl)C(C)=CC(C=2C=3CN(CCC=3N(CC(O)CN3CCC(CC3)N3C(NC4=CC=C(Cl)C=C43)=O)N=2)S(C)(=O)=O)=C1 UCQLUWCPLPDLFX-UHFFFAOYSA-N 0.000 claims description 2
- PPNRZJCYXTWNEF-UHFFFAOYSA-N 6-chloro-1-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-3,4-dihydroquinazolin-2-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C4=CC=C(Cl)C=C4CNC3=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 PPNRZJCYXTWNEF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000006187 phenyl benzyl group Chemical group 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 459
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 324
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 290
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 269
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 188
- 239000000203 mixture Substances 0.000 description 172
- 239000000377 silicon dioxide Substances 0.000 description 142
- 235000019439 ethyl acetate Nutrition 0.000 description 134
- 239000000243 solution Substances 0.000 description 124
- 238000005160 1H NMR spectroscopy Methods 0.000 description 103
- 238000003756 stirring Methods 0.000 description 92
- 239000007787 solid Substances 0.000 description 88
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 87
- 239000007832 Na2SO4 Substances 0.000 description 83
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 83
- 229910052938 sodium sulfate Inorganic materials 0.000 description 83
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 80
- 229910001868 water Inorganic materials 0.000 description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 79
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 74
- 238000004809 thin layer chromatography Methods 0.000 description 74
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 70
- 239000002904 solvent Substances 0.000 description 65
- 230000002829 reductive effect Effects 0.000 description 61
- 239000010410 layer Substances 0.000 description 58
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 52
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 52
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 46
- 239000012044 organic layer Substances 0.000 description 43
- 239000003921 oil Substances 0.000 description 42
- 235000019198 oils Nutrition 0.000 description 42
- 239000011541 reaction mixture Substances 0.000 description 42
- 238000004440 column chromatography Methods 0.000 description 41
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- 239000012267 brine Substances 0.000 description 36
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 36
- 108090000613 Cathepsin S Proteins 0.000 description 35
- 210000001744 T-lymphocyte Anatomy 0.000 description 35
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 239000000284 extract Substances 0.000 description 31
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 30
- 238000000746 purification Methods 0.000 description 30
- 102100035654 Cathepsin S Human genes 0.000 description 27
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 27
- 239000011734 sodium Substances 0.000 description 26
- 230000005764 inhibitory process Effects 0.000 description 25
- 239000012043 crude product Substances 0.000 description 24
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 24
- 229940122805 Cathepsin S inhibitor Drugs 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 238000003818 flash chromatography Methods 0.000 description 20
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 19
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 17
- 239000013566 allergen Substances 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 208000010668 atopic eczema Diseases 0.000 description 15
- 150000003254 radicals Chemical group 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 13
- 230000000172 allergic effect Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 12
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 235000003484 annual ragweed Nutrition 0.000 description 12
- 235000006263 bur ragweed Nutrition 0.000 description 12
- 229910000024 caesium carbonate Inorganic materials 0.000 description 12
- 235000003488 common ragweed Nutrition 0.000 description 12
- 230000009696 proliferative response Effects 0.000 description 12
- 235000009736 ragweed Nutrition 0.000 description 12
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 208000026935 allergic disease Diseases 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 10
- 229960004784 allergens Drugs 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 229910020323 ClF3 Inorganic materials 0.000 description 9
- 229940074608 allergen extract Drugs 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- SYEZRHZJCHIWHV-UHFFFAOYSA-N 1-[1-(oxiran-2-ylmethyl)-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC2=C1C(C=1C=CC(=CC=1)C(F)(F)F)=NN2CC1CO1 SYEZRHZJCHIWHV-UHFFFAOYSA-N 0.000 description 8
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 8
- MFICZYBNZJIOPQ-UHFFFAOYSA-N 5-methylsulfonyl-1-(oxiran-2-ylmethyl)-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine Chemical compound C1N(S(=O)(=O)C)CCC2=C1C(C=1C=CC(=CC=1)C(F)(F)F)=NN2CC1CO1 MFICZYBNZJIOPQ-UHFFFAOYSA-N 0.000 description 7
- 108010062580 Concanavalin A Proteins 0.000 description 7
- 241000238711 Pyroglyphidae Species 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 229940046533 house dust mites Drugs 0.000 description 7
- 229930195733 hydrocarbon Natural products 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 108010028930 invariant chain Proteins 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 238000002390 rotary evaporation Methods 0.000 description 7
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 239000010779 crude oil Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 229940086542 triethylamine Drugs 0.000 description 6
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 5
- IJXWCLGGHOLJGH-UHFFFAOYSA-N 5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine Chemical compound C1=2CN(S(=O)(=O)C)CCC=2NN=C1C1=CC=C(C(F)(F)F)C=C1 IJXWCLGGHOLJGH-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical class CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
- 150000002081 enamines Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- STEAYGPTLHZMJU-UHFFFAOYSA-N tert-butyl 4-(2-oxo-3h-benzimidazol-1-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C(=O)NC2=CC=CC=C21 STEAYGPTLHZMJU-UHFFFAOYSA-N 0.000 description 5
- QMNAEELIWJCDBE-UHFFFAOYSA-N 1-[3-(4-chloro-3-methylphenyl)-1-(oxiran-2-ylmethyl)-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC2=C1C(C=1C=C(C)C(Cl)=CC=1)=NN2CC1CO1 QMNAEELIWJCDBE-UHFFFAOYSA-N 0.000 description 4
- NNFOVLFUGLWWCL-UHFFFAOYSA-N 1-acetylpiperidin-4-one Chemical compound CC(=O)N1CCC(=O)CC1 NNFOVLFUGLWWCL-UHFFFAOYSA-N 0.000 description 4
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 4
- 102400001295 Class-II-associated invariant chain peptide Human genes 0.000 description 4
- 101800001887 Class-II-associated invariant chain peptide Proteins 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 150000005217 methyl ethers Chemical class 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- 0 *C(CC1)C(*)CN1*=C Chemical compound *C(CC1)C(*)CN1*=C 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- DHUVOYUNPQCHLM-UHFFFAOYSA-N 1-[3-(4-chloro-3-methylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1=2CN(C(=O)C)CCC=2NN=C1C1=CC=C(Cl)C(C)=C1 DHUVOYUNPQCHLM-UHFFFAOYSA-N 0.000 description 3
- NSLQIVWJEANHBF-UHFFFAOYSA-N 1-methyl-3-[1-[3-[3-[4-(trifluoromethyl)phenyl]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]benzimidazol-2-one Chemical compound O=C1N(C)C2=CC=CC=C2N1C(CC1)CCN1CCCN(C=1CCNCC=11)N=C1C1=CC=C(C(F)(F)F)C=C1 NSLQIVWJEANHBF-UHFFFAOYSA-N 0.000 description 3
- VEWTUUDVRSEVLC-UHFFFAOYSA-N 1-methyl-3-piperidin-4-ylbenzimidazol-2-one Chemical compound O=C1N(C)C2=CC=CC=C2N1C1CCNCC1 VEWTUUDVRSEVLC-UHFFFAOYSA-N 0.000 description 3
- OGWQFVXGUUSQMD-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethyl)-3-[4-(trifluoromethyl)phenyl]pyrazol-4-yl]pyrazine Chemical compound C1=CC(C(F)(F)F)=CC=C1C(C(=C1)C=2N=CC=NC=2)=NN1CC1OC1 OGWQFVXGUUSQMD-UHFFFAOYSA-N 0.000 description 3
- MKYGARNTUSGEEH-UHFFFAOYSA-N 3-[1-[3-[3-(3,4-dichlorophenyl)-5-methylsulfonyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CCCN3CCC(CC3)N3C(NC4=CC=CC=C43)=O)=C1C=2C1=CC=C(Cl)C(Cl)=C1 MKYGARNTUSGEEH-UHFFFAOYSA-N 0.000 description 3
- AKPHPDLNLFGGTJ-UHFFFAOYSA-N 3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propan-1-ol Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CCCO)=C1C=2C1=CC=C(C(F)(F)F)C=C1 AKPHPDLNLFGGTJ-UHFFFAOYSA-N 0.000 description 3
- BYNBAMHAURJNTR-UHFFFAOYSA-N 3-piperidin-4-yl-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C1CCNCC1 BYNBAMHAURJNTR-UHFFFAOYSA-N 0.000 description 3
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 3
- OXZYBOLWRXENKT-UHFFFAOYSA-N 4-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=O)C=C1 OXZYBOLWRXENKT-UHFFFAOYSA-N 0.000 description 3
- CLFRCMDLPMBAKH-UHFFFAOYSA-N 4-[1-(oxiran-2-ylmethyl)-3-[4-(trifluoromethyl)phenyl]pyrazol-4-yl]pyridine Chemical compound C1=CC(C(F)(F)F)=CC=C1C(C(=C1)C=2C=CN=CC=2)=NN1CC1OC1 CLFRCMDLPMBAKH-UHFFFAOYSA-N 0.000 description 3
- AUAGYRAAUGIPBE-UHFFFAOYSA-N 5-(dimethylamino)-1-methyl-3-piperidin-4-ylimidazo[4,5-b]pyridin-2-one Chemical compound C12=NC(N(C)C)=CC=C2N(C)C(=O)N1C1CCNCC1 AUAGYRAAUGIPBE-UHFFFAOYSA-N 0.000 description 3
- ONPNSGSNBLVKRS-UHFFFAOYSA-N 5-chloro-1-methyl-3-piperidin-4-ylbenzimidazol-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2N1C1CCNCC1 ONPNSGSNBLVKRS-UHFFFAOYSA-N 0.000 description 3
- FJCHFVDZYLYFBX-UHFFFAOYSA-N 5-chloro-3-piperidin-4-yl-1h-benzimidazol-2-one Chemical compound C12=CC(Cl)=CC=C2NC(=O)N1C1CCNCC1 FJCHFVDZYLYFBX-UHFFFAOYSA-N 0.000 description 3
- MFICZYBNZJIOPQ-CYBMUJFWSA-N 5-methylsulfonyl-1-[[(2r)-oxiran-2-yl]methyl]-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine Chemical compound C1N(S(=O)(=O)C)CCC2=C1C(C=1C=CC(=CC=1)C(F)(F)F)=NN2C[C@@H]1CO1 MFICZYBNZJIOPQ-CYBMUJFWSA-N 0.000 description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 3
- 101100152731 Arabidopsis thaliana TH2 gene Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 208000004262 Food Hypersensitivity Diseases 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 3
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- KJWQGMCWDYSRKT-UHFFFAOYSA-N ethyl 2-[3-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-2-oxobenzimidazol-1-yl]acetate Chemical compound O=C1N(CC(=O)OCC)C2=CC=CC=C2N1C(CC1)CCN1CC(O)CN(C=1CCN(CC=11)S(C)(=O)=O)N=C1C1=CC=C(C(F)(F)F)C=C1 KJWQGMCWDYSRKT-UHFFFAOYSA-N 0.000 description 3
- DUADMNJPVOFXOI-UHFFFAOYSA-N ethyl 4-(6-chloro-2-oxo-3h-benzimidazol-1-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1N1C(=O)NC2=CC=C(Cl)C=C21 DUADMNJPVOFXOI-UHFFFAOYSA-N 0.000 description 3
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 3
- 238000010228 ex vivo assay Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 235000020932 food allergy Nutrition 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- BWQBYHGDMBHIIQ-UHFFFAOYSA-N methyl 2-(2-aminophenyl)acetate Chemical compound COC(=O)CC1=CC=CC=C1N BWQBYHGDMBHIIQ-UHFFFAOYSA-N 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 238000012746 preparative thin layer chromatography Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- PTHJMLADCCAMSN-UHFFFAOYSA-N tert-butyl 4-[2-(aminomethyl)-4-chloroanilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=C(Cl)C=C1CN PTHJMLADCCAMSN-UHFFFAOYSA-N 0.000 description 3
- YANSSVVGZPNSKD-MRVPVSSYSA-N tert-butyl-dimethyl-[[(2r)-oxiran-2-yl]methoxy]silane Chemical compound CC(C)(C)[Si](C)(C)OC[C@H]1CO1 YANSSVVGZPNSKD-MRVPVSSYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical compound [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 2
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 description 2
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
- JQYYDAPQCHWQCC-UHFFFAOYSA-N 1-(4-piperidinyl)-1,3-dihydro-2h-indol-2-one Chemical compound O=C1CC2=CC=CC=C2N1C1CCNCC1 JQYYDAPQCHWQCC-UHFFFAOYSA-N 0.000 description 2
- KIPIDPRRXSGVEY-UHFFFAOYSA-N 1-[1-[3-[4-(1h-benzimidazol-2-yl)piperidin-1-yl]-2-hydroxypropyl]-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)C=3NC4=CC=CC=C4N=3)=C1C=2C1=CC=C(C(F)(F)F)C=C1 KIPIDPRRXSGVEY-UHFFFAOYSA-N 0.000 description 2
- XTGJFYAMBFOQNL-UHFFFAOYSA-N 1-[3-(4-bromophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1=2CN(C(=O)C)CCC=2NN=C1C1=CC=C(Br)C=C1 XTGJFYAMBFOQNL-UHFFFAOYSA-N 0.000 description 2
- OGNQUNXULUEASU-UHFFFAOYSA-N 1-[3-(4-bromophenyl)-1-(oxiran-2-ylmethyl)-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC2=C1C(C=1C=CC(Br)=CC=1)=NN2CC1CO1 OGNQUNXULUEASU-UHFFFAOYSA-N 0.000 description 2
- BMYLXIPPHZTQDQ-CQSZACIVSA-N 1-[3-(4-chloro-3-methylphenyl)-1-[(2r)-2,3-dihydroxypropyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC(N(N=2)C[C@@H](O)CO)=C1C=2C1=CC=C(Cl)C(C)=C1 BMYLXIPPHZTQDQ-CQSZACIVSA-N 0.000 description 2
- QMNAEELIWJCDBE-CQSZACIVSA-N 1-[3-(4-chloro-3-methylphenyl)-1-[[(2r)-oxiran-2-yl]methyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC2=C1C(C=1C=C(C)C(Cl)=CC=1)=NN2C[C@@H]1CO1 QMNAEELIWJCDBE-CQSZACIVSA-N 0.000 description 2
- GTPHRNWPBYLYQT-UHFFFAOYSA-N 1-[3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1=2CN(C(=O)C)CCC=2NN=C1C1=CC=C(Cl)C=C1 GTPHRNWPBYLYQT-UHFFFAOYSA-N 0.000 description 2
- PCJNEHZLABIQLP-UHFFFAOYSA-N 1-[3-(4-chlorophenyl)-1-(oxiran-2-ylmethyl)-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC2=C1C(C=1C=CC(Cl)=CC=1)=NN2CC1CO1 PCJNEHZLABIQLP-UHFFFAOYSA-N 0.000 description 2
- LEXJVWVRNOCMGE-UHFFFAOYSA-N 1-[3-(4-chlorophenyl)-1-[3-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-hydroxypropyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1N(C(=O)C)CCC2=C1C(C=1C=CC(Cl)=CC=1)=NN2CC(O)CN(CC1)CCC21OCCO2 LEXJVWVRNOCMGE-UHFFFAOYSA-N 0.000 description 2
- XPRXJFYBFCGWNR-UHFFFAOYSA-N 1-[3-[4-(3-methyl-2-oxobenzimidazol-1-yl)piperidin-1-yl]propyl]-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-sulfonic acid Chemical compound O=C1N(C)C2=CC=CC=C2N1C(CC1)CCN1CCCN(C=1CCN(CC=11)S(O)(=O)=O)N=C1C1=CC=C(C(F)(F)F)C=C1 XPRXJFYBFCGWNR-UHFFFAOYSA-N 0.000 description 2
- RVIDQDPIXGFLHZ-UHFFFAOYSA-N 1-[3-[4-(trifluoromethyl)phenyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone Chemical compound C1=2CN(C(=O)C)CCC=2NN=C1C1=CC=C(C(F)(F)F)C=C1 RVIDQDPIXGFLHZ-UHFFFAOYSA-N 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 2
- HTXSCMQHTMIMTD-UHFFFAOYSA-N 1-piperidin-4-yl-2,3-dihydroindole Chemical compound C1CC2=CC=CC=C2N1C1CCNCC1 HTXSCMQHTMIMTD-UHFFFAOYSA-N 0.000 description 2
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 2
- CQTRJWBXQRDCFD-UHFFFAOYSA-N 2-(2-oxo-3-piperidin-4-ylbenzimidazol-1-yl)acetonitrile Chemical compound O=C1N(CC#N)C2=CC=CC=C2N1C1CCNCC1 CQTRJWBXQRDCFD-UHFFFAOYSA-N 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
- PSMCLLRDPLNGQT-UHFFFAOYSA-N 2-[2-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]amino]phenoxy]acetic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=CC=C1OCC(O)=O PSMCLLRDPLNGQT-UHFFFAOYSA-N 0.000 description 2
- AYROSXFGAMYUJP-UHFFFAOYSA-N 2-[3-[1-[3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-2-oxobenzimidazol-1-yl]acetonitrile Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CCCN3CCC(CC3)N3C(N(CC#N)C4=CC=CC=C43)=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 AYROSXFGAMYUJP-UHFFFAOYSA-N 0.000 description 2
- SWFNPENEBHAHEB-UHFFFAOYSA-N 2-amino-4-chlorophenol Chemical compound NC1=CC(Cl)=CC=C1O SWFNPENEBHAHEB-UHFFFAOYSA-N 0.000 description 2
- HBOGHPAOOWUTLB-UHFFFAOYSA-N 2-piperidin-4-yl-1h-benzimidazole Chemical compound C1CNCCC1C1=NC2=CC=CC=C2N1 HBOGHPAOOWUTLB-UHFFFAOYSA-N 0.000 description 2
- TVCHTNHZBYJKSL-UHFFFAOYSA-N 2-piperidin-4-yl-5-(trifluoromethyl)-1,3-benzothiazole Chemical compound N=1C2=CC(C(F)(F)F)=CC=C2SC=1C1CCNCC1 TVCHTNHZBYJKSL-UHFFFAOYSA-N 0.000 description 2
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- SOXBCSBXQBURHC-UHFFFAOYSA-N 3-(4-bromophenyl)-4,5,6,7-tetrahydro-2h-pyrazolo[4,3-c]pyridin-2-ium;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C1=CC(Br)=CC=C1C1=N[NH2+]C2=C1CNCC2 SOXBCSBXQBURHC-UHFFFAOYSA-N 0.000 description 2
- UZFOWVXTQSMGLX-UHFFFAOYSA-N 3-(4-bromophenyl)-5-methylsulfonyl-1-(oxiran-2-ylmethyl)-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine Chemical compound C1N(S(=O)(=O)C)CCC2=C1C(C=1C=CC(Br)=CC=1)=NN2CC1CO1 UZFOWVXTQSMGLX-UHFFFAOYSA-N 0.000 description 2
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 2
- BKOASLQLTJLPLS-UHFFFAOYSA-N 3-[1-[2-hydroxy-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CC(O)CN3CCC(CC3)N3C(NC4=CC=CC=C43)=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 BKOASLQLTJLPLS-UHFFFAOYSA-N 0.000 description 2
- CFGSTQVIHPJXGT-UHFFFAOYSA-N 3-[5-chloro-2-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]amino]phenyl]propanoic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=C(Cl)C=C1CCC(O)=O CFGSTQVIHPJXGT-UHFFFAOYSA-N 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 2
- SDARRYSVKYQEIW-UHFFFAOYSA-N 3-piperidin-4-yl-1,3-benzoxazol-2-one Chemical compound O=C1OC=2C=CC=CC=2N1C1CCNCC1 SDARRYSVKYQEIW-UHFFFAOYSA-N 0.000 description 2
- ZSLGVOFOMAZXJU-UHFFFAOYSA-N 4-(3,4-dichlorophenoxy)piperidine;2,2,2-trifluoroacetic acid Chemical compound [O-]C(=O)C(F)(F)F.C1=C(Cl)C(Cl)=CC=C1OC1CC[NH2+]CC1 ZSLGVOFOMAZXJU-UHFFFAOYSA-N 0.000 description 2
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 2
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 2
- CFNILHOXUHJXOT-UHFFFAOYSA-N 4-piperidin-4-ylpyrido[3,2-b][1,4]oxazin-3-one Chemical compound O=C1COC2=CC=CN=C2N1C1CCNCC1 CFNILHOXUHJXOT-UHFFFAOYSA-N 0.000 description 2
- BNGYHMIMGZWGSY-UHFFFAOYSA-N 5-chloro-1-piperidin-4-yl-3h-indol-2-one Chemical compound O=C1CC2=CC(Cl)=CC=C2N1C1CCNCC1 BNGYHMIMGZWGSY-UHFFFAOYSA-N 0.000 description 2
- FMIRHORUZHTADH-UHFFFAOYSA-N 5-chloro-2-(2,2-dimethoxyethyl)aniline Chemical compound COC(OC)CC1=CC=C(Cl)C=C1N FMIRHORUZHTADH-UHFFFAOYSA-N 0.000 description 2
- CTXQQZDBUIIQFM-UHFFFAOYSA-N 5-chloro-2-piperidin-4-yl-1,3-benzoxazole Chemical compound N=1C2=CC(Cl)=CC=C2OC=1C1CCNCC1 CTXQQZDBUIIQFM-UHFFFAOYSA-N 0.000 description 2
- DLFCGYFNRRTDQI-UHFFFAOYSA-N 6-chloro-1-piperidin-4-yl-3,4-dihydro-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound O=S1(=O)NCC2=CC(Cl)=CC=C2N1C1CCNCC1 DLFCGYFNRRTDQI-UHFFFAOYSA-N 0.000 description 2
- GFARZSIMWFGBMD-UHFFFAOYSA-N 6-chloro-1-piperidin-4-yl-3,4-dihydroquinazolin-2-one Chemical compound O=C1NCC2=CC(Cl)=CC=C2N1C1CCNCC1 GFARZSIMWFGBMD-UHFFFAOYSA-N 0.000 description 2
- IMHHXXQTUICFIZ-UHFFFAOYSA-N 6-chloro-1-piperidin-4-yl-3,4-dihydroquinolin-2-one Chemical compound O=C1CCC2=CC(Cl)=CC=C2N1C1CCNCC1 IMHHXXQTUICFIZ-UHFFFAOYSA-N 0.000 description 2
- DEETUXXCWLAUOS-UHFFFAOYSA-N 6-chloro-1-piperidin-4-ylindole Chemical compound C12=CC(Cl)=CC=C2C=CN1C1CCNCC1 DEETUXXCWLAUOS-UHFFFAOYSA-N 0.000 description 2
- RTWKUSAOTKMZMU-UHFFFAOYSA-N 6-chloro-4-piperidin-4-yl-1,4-benzoxazin-3-one Chemical compound C12=CC(Cl)=CC=C2OCC(=O)N1C1CCNCC1 RTWKUSAOTKMZMU-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 241000208839 Ambrosia Species 0.000 description 2
- 241000208841 Ambrosia trifida Species 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 229910019020 PtO2 Inorganic materials 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000010936 aqueous wash Methods 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- PMKKZVUTFRIIDN-UHFFFAOYSA-N diethyl 2-(5-chloro-2-nitrophenyl)propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)C1=CC(Cl)=CC=C1[N+]([O-])=O PMKKZVUTFRIIDN-UHFFFAOYSA-N 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- MOPKQQCRURVIKB-UHFFFAOYSA-N ethyl 2-(2-amino-5-chlorophenyl)acetate Chemical compound CCOC(=O)CC1=CC(Cl)=CC=C1N MOPKQQCRURVIKB-UHFFFAOYSA-N 0.000 description 2
- CAVIDEZCVXRIRS-UHFFFAOYSA-N ethyl 2-(5-chloro-2-nitrophenyl)acetate Chemical compound CCOC(=O)CC1=CC(Cl)=CC=C1[N+]([O-])=O CAVIDEZCVXRIRS-UHFFFAOYSA-N 0.000 description 2
- XEMYJRCJEPZTGM-UHFFFAOYSA-N ethyl 3-(2-amino-5-chlorophenyl)prop-2-enoate Chemical compound CCOC(=O)C=CC1=CC(Cl)=CC=C1N XEMYJRCJEPZTGM-UHFFFAOYSA-N 0.000 description 2
- TYZPQQYEGVWDNR-UHFFFAOYSA-N ethyl 4-(5-chloro-2-nitroanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=CC(Cl)=CC=C1[N+]([O-])=O TYZPQQYEGVWDNR-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- SWMFAAPTSMVULA-UHFFFAOYSA-N methyl 2-(2-nitrophenyl)acetate Chemical compound COC(=O)CC1=CC=CC=C1[N+]([O-])=O SWMFAAPTSMVULA-UHFFFAOYSA-N 0.000 description 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000013014 purified material Substances 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000007390 skin biopsy Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000003638 stannyl group Chemical group [H][Sn]([H])([H])* 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VHWRIHRIBNAHGV-UHFFFAOYSA-N tert-butyl 1-(3-hydroxypropyl)-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(N(N=2)CCCO)=C1C=2C1=CC=C(C(F)(F)F)C=C1 VHWRIHRIBNAHGV-UHFFFAOYSA-N 0.000 description 2
- LPKRWRKHSCLFHA-UHFFFAOYSA-N tert-butyl 1-(3-methoxy-3-oxopropyl)-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carboxylate Chemical compound C1=2CN(C(=O)OC(C)(C)C)CCC=2N(CCC(=O)OC)N=C1C1=CC=C(C(F)(F)F)C=C1 LPKRWRKHSCLFHA-UHFFFAOYSA-N 0.000 description 2
- GPFWLGPBSKFRJT-UHFFFAOYSA-N tert-butyl 1-(3-oxopropyl)-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(N(N=2)CCC=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 GPFWLGPBSKFRJT-UHFFFAOYSA-N 0.000 description 2
- RTZMPSHIBRGWKE-UHFFFAOYSA-N tert-butyl 1-[3-[4-(3-methyl-2-oxobenzimidazol-1-yl)piperidin-1-yl]propyl]-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carboxylate Chemical compound O=C1N(C)C2=CC=CC=C2N1C(CC1)CCN1CCCN(C=1CCN(CC=11)C(=O)OC(C)(C)C)N=C1C1=CC=C(C(F)(F)F)C=C1 RTZMPSHIBRGWKE-UHFFFAOYSA-N 0.000 description 2
- IHZIDVVEZYXESH-UHFFFAOYSA-N tert-butyl 3-(4-bromophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate Chemical compound C1=2CN(C(=O)OC(C)(C)C)CCC=2NN=C1C1=CC=C(Br)C=C1 IHZIDVVEZYXESH-UHFFFAOYSA-N 0.000 description 2
- WTMJPYAELCEARF-UHFFFAOYSA-N tert-butyl 3-[4-(trifluoromethyl)phenyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate Chemical compound C1=2CN(C(=O)OC(C)(C)C)CCC=2NN=C1C1=CC=C(C(F)(F)F)C=C1 WTMJPYAELCEARF-UHFFFAOYSA-N 0.000 description 2
- MELQMERUDGGYLG-UHFFFAOYSA-N tert-butyl 4-(1,2-benzoxazol-3-yloxy)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NOC2=CC=CC=C12 MELQMERUDGGYLG-UHFFFAOYSA-N 0.000 description 2
- IMDQYVGELRGYHF-UHFFFAOYSA-N tert-butyl 4-(1,3-benzothiazol-2-ylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=NC2=CC=CC=C2S1 IMDQYVGELRGYHF-UHFFFAOYSA-N 0.000 description 2
- HJKUNABSNYEGJB-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=CC=C1O HJKUNABSNYEGJB-UHFFFAOYSA-N 0.000 description 2
- AUWQQLLBNFTTNY-UHFFFAOYSA-N tert-butyl 4-(2-oxo-1,3-benzoxazol-3-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C(=O)OC2=CC=CC=C21 AUWQQLLBNFTTNY-UHFFFAOYSA-N 0.000 description 2
- LWJUTDROJPEMKB-UHFFFAOYSA-N tert-butyl 4-(2-oxo-3h-indol-1-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C2=CC=CC=C2CC1=O LWJUTDROJPEMKB-UHFFFAOYSA-N 0.000 description 2
- KMEPIVRXUQKHOI-UHFFFAOYSA-N tert-butyl 4-(3,5-dichloropyridin-4-yl)oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=C(Cl)C=NC=C1Cl KMEPIVRXUQKHOI-UHFFFAOYSA-N 0.000 description 2
- SWTSTIPEZSPISD-UHFFFAOYSA-N tert-butyl 4-(3-oxo-1,4-benzoxazin-4-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C2=CC=CC=C2OCC1=O SWTSTIPEZSPISD-UHFFFAOYSA-N 0.000 description 2
- MZDAACSOBOIYJA-UHFFFAOYSA-N tert-butyl 4-(5-chloro-2-hydroxyanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC(Cl)=CC=C1O MZDAACSOBOIYJA-UHFFFAOYSA-N 0.000 description 2
- QAOKLFWMTNIMFA-UHFFFAOYSA-N tert-butyl 4-(5-chloro-2-oxo-3h-indol-1-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C2=CC=C(Cl)C=C2CC1=O QAOKLFWMTNIMFA-UHFFFAOYSA-N 0.000 description 2
- ZEJIWSBAVZNADK-UHFFFAOYSA-N tert-butyl 4-(5-chloro-n-(2-ethoxy-2-oxoethyl)-2-hydroxyanilino)piperidine-1-carboxylate Chemical compound C=1C(Cl)=CC=C(O)C=1N(CC(=O)OCC)C1CCN(C(=O)OC(C)(C)C)CC1 ZEJIWSBAVZNADK-UHFFFAOYSA-N 0.000 description 2
- SGXRMKPLIBLXSG-UHFFFAOYSA-N tert-butyl 4-(6-chloro-2-oxo-3,4-dihydroquinazolin-1-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C2=CC=C(Cl)C=C2CNC1=O SGXRMKPLIBLXSG-UHFFFAOYSA-N 0.000 description 2
- QOQNNBWHYCQEIU-UHFFFAOYSA-N tert-butyl 4-(6-chloro-3-oxo-1,4-benzoxazin-4-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C2=CC(Cl)=CC=C2OCC1=O QOQNNBWHYCQEIU-UHFFFAOYSA-N 0.000 description 2
- SEJCRTJGKJJZRS-UHFFFAOYSA-N tert-butyl 4-[(3-hydroxypyridin-2-yl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=NC=CC=C1O SEJCRTJGKJJZRS-UHFFFAOYSA-N 0.000 description 2
- NXMUCRGLBUGIAB-UHFFFAOYSA-N tert-butyl 4-[(6-chloro-3-nitropyridin-2-yl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=NC(Cl)=CC=C1[N+]([O-])=O NXMUCRGLBUGIAB-UHFFFAOYSA-N 0.000 description 2
- HDMUEYNMJIAHAR-UHFFFAOYSA-N tert-butyl 4-[2-(2-ethoxy-2-oxoethoxy)anilino]piperidine-1-carboxylate Chemical compound CCOC(=O)COC1=CC=CC=C1NC1CCN(C(=O)OC(C)(C)C)CC1 HDMUEYNMJIAHAR-UHFFFAOYSA-N 0.000 description 2
- MFFLPVHPOSLVQT-UHFFFAOYSA-N tert-butyl 4-[4-chloro-2-(3-ethoxy-3-oxoprop-1-enyl)anilino]piperidine-1-carboxylate Chemical compound CCOC(=O)C=CC1=CC(Cl)=CC=C1NC1CCN(C(=O)OC(C)(C)C)CC1 MFFLPVHPOSLVQT-UHFFFAOYSA-N 0.000 description 2
- SZBADBIHGGLHJT-UHFFFAOYSA-N tert-butyl 4-[4-chloro-2-(3-ethoxy-3-oxopropyl)anilino]piperidine-1-carboxylate Chemical compound CCOC(=O)CCC1=CC(Cl)=CC=C1NC1CCN(C(=O)OC(C)(C)C)CC1 SZBADBIHGGLHJT-UHFFFAOYSA-N 0.000 description 2
- MXKOBPAPDJMBCZ-UHFFFAOYSA-N tert-butyl 4-[5-(dimethylamino)-1-methyl-2-oxoimidazo[4,5-b]pyridin-3-yl]piperidine-1-carboxylate Chemical compound C12=NC(N(C)C)=CC=C2N(C)C(=O)N1C1CCN(C(=O)OC(C)(C)C)CC1 MXKOBPAPDJMBCZ-UHFFFAOYSA-N 0.000 description 2
- FVIZEFBYLGZVHY-UHFFFAOYSA-N tert-butyl 4-[5-chloro-2-(2,2-dimethoxyethyl)anilino]piperidine-1-carboxylate Chemical compound COC(OC)CC1=CC=C(Cl)C=C1NC1CCN(C(=O)OC(C)(C)C)CC1 FVIZEFBYLGZVHY-UHFFFAOYSA-N 0.000 description 2
- SJOHVBJFZVIFFV-UHFFFAOYSA-N tert-butyl 4-[[3-(2-ethoxy-2-oxoethoxy)pyridin-2-yl]amino]piperidine-1-carboxylate Chemical compound CCOC(=O)COC1=CC=CN=C1NC1CCN(C(=O)OC(C)(C)C)CC1 SJOHVBJFZVIFFV-UHFFFAOYSA-N 0.000 description 2
- HDJWRZAEDOVOIJ-UHFFFAOYSA-N tert-butyl 4-[[6-(dimethylamino)-3-nitropyridin-2-yl]amino]piperidine-1-carboxylate Chemical compound CN(C)C1=CC=C([N+]([O-])=O)C(NC2CCN(CC2)C(=O)OC(C)(C)C)=N1 HDJWRZAEDOVOIJ-UHFFFAOYSA-N 0.000 description 2
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WMUZDBZPDLHUMW-UHFFFAOYSA-N (2-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1[N+]([O-])=O WMUZDBZPDLHUMW-UHFFFAOYSA-N 0.000 description 1
- HIMRIMBJBMKWPE-CYBMUJFWSA-N (2r)-3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propane-1,2-diol Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)C[C@@H](O)CO)=C1C=2C1=CC=C(C(F)(F)F)C=C1 HIMRIMBJBMKWPE-CYBMUJFWSA-N 0.000 description 1
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- CTKINSOISVBQLD-VKHMYHEASA-N (S)-Glycidol Chemical compound OC[C@H]1CO1 CTKINSOISVBQLD-VKHMYHEASA-N 0.000 description 1
- ZOJKRWXDNYZASL-NSCUHMNNSA-N (e)-4-methoxybut-2-enoic acid Chemical compound COC\C=C\C(O)=O ZOJKRWXDNYZASL-NSCUHMNNSA-N 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- SMWUDAKKCDQTPV-UHFFFAOYSA-N 1,3-dimethylimidazolidine Chemical class CN1CCN(C)C1 SMWUDAKKCDQTPV-UHFFFAOYSA-N 0.000 description 1
- 150000000093 1,3-dioxanes Chemical class 0.000 description 1
- 125000006091 1,3-dioxolane group Chemical class 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical class C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 description 1
- KPKNTUUIEVXMOH-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCNCC1 KPKNTUUIEVXMOH-UHFFFAOYSA-N 0.000 description 1
- RWYYNSXVFPESMC-UHFFFAOYSA-N 1,5-dihydro-2,4-benzodioxepine Chemical compound C1OCOCC2=CC=CC=C21 RWYYNSXVFPESMC-UHFFFAOYSA-N 0.000 description 1
- XKBZAEGUFRRDCW-UHFFFAOYSA-N 1,5-dihydro-2,4-benzodithiepine Chemical compound C1SCSCC2=CC=CC=C21 XKBZAEGUFRRDCW-UHFFFAOYSA-N 0.000 description 1
- ZLQMPDPTSXTWEM-UHFFFAOYSA-N 1-[3-[5-acetyl-3-(4-chlorophenyl)-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-one Chemical compound C1N(C(=O)C)CCC2=C1C(C=1C=CC(Cl)=CC=1)=NN2CC(O)CN1CCC(=O)CC1 ZLQMPDPTSXTWEM-UHFFFAOYSA-N 0.000 description 1
- MNCMBBIFTVWHIP-UHFFFAOYSA-N 1-anthracen-9-yl-2,2,2-trifluoroethanone Chemical group C1=CC=C2C(C(=O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 MNCMBBIFTVWHIP-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- ATPQHBQUXWELOE-UHFFFAOYSA-N 1-hydroxysulfanyl-2,4-dinitrobenzene Chemical compound OSC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O ATPQHBQUXWELOE-UHFFFAOYSA-N 0.000 description 1
- RNFJPQFPCGBCFZ-UHFFFAOYSA-N 1-n,2-n-bis[(3,4-dimethoxyphenyl)methyl]propane-1,2-diamine;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CNCC(C)NCC1=CC=C(OC)C(OC)=C1 RNFJPQFPCGBCFZ-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- SIZIQJKLJZWLLD-UHFFFAOYSA-N 1-piperidin-1-ium-4-ylbenzotriazole;chloride Chemical compound [Cl-].C1C[NH2+]CCC1N1C2=CC=CC=C2N=N1 SIZIQJKLJZWLLD-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- WOHLSTOWRAOMSG-UHFFFAOYSA-N 2,3-dihydro-1,3-benzothiazole Chemical class C1=CC=C2SCNC2=C1 WOHLSTOWRAOMSG-UHFFFAOYSA-N 0.000 description 1
- FFFIRKXTFQCCKJ-UHFFFAOYSA-M 2,4,6-trimethylbenzoate Chemical compound CC1=CC(C)=C(C([O-])=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-M 0.000 description 1
- QUIMTLZDMCNYGY-UHFFFAOYSA-N 2,4-dichloro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1Cl QUIMTLZDMCNYGY-UHFFFAOYSA-N 0.000 description 1
- SHCWQWRTKPNTEM-UHFFFAOYSA-N 2,6-dichloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1Cl SHCWQWRTKPNTEM-UHFFFAOYSA-N 0.000 description 1
- YAIUOMMSSSVJLB-UHFFFAOYSA-N 2-(1,3-dioxan-5-yl)pyridine Chemical compound C1OCOCC1C1=CC=CC=N1 YAIUOMMSSSVJLB-UHFFFAOYSA-N 0.000 description 1
- YURLCYGZYWDCHL-UHFFFAOYSA-N 2-(2,6-dichloro-4-methylphenoxy)acetic acid Chemical compound CC1=CC(Cl)=C(OCC(O)=O)C(Cl)=C1 YURLCYGZYWDCHL-UHFFFAOYSA-N 0.000 description 1
- PUVGBKOHDJUFRZ-UHFFFAOYSA-N 2-(2-pyridin-3-ylpiperidin-1-yl)acetonitrile Chemical compound N#CCN1CCCCC1C1=CC=CN=C1 PUVGBKOHDJUFRZ-UHFFFAOYSA-N 0.000 description 1
- TYYAMZMDZWXHHA-UHFFFAOYSA-N 2-(dibromomethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(Br)Br TYYAMZMDZWXHHA-UHFFFAOYSA-N 0.000 description 1
- NEESBXODYBPTFM-UHFFFAOYSA-N 2-(methylsulfanylmethoxy)ethyl hydrogen carbonate Chemical compound CSCOCCOC(O)=O NEESBXODYBPTFM-UHFFFAOYSA-N 0.000 description 1
- JGYNXZIYXGSEJH-UHFFFAOYSA-N 2-(methylsulfanylmethoxymethyl)benzoic acid Chemical compound CSCOCC1=CC=CC=C1C(O)=O JGYNXZIYXGSEJH-UHFFFAOYSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- QXQMENSTZKYZCE-UHFFFAOYSA-N 2-[2,4-bis(2-methylbutan-2-yl)phenoxy]acetic acid Chemical compound CCC(C)(C)C1=CC=C(OCC(O)=O)C(C(C)(C)CC)=C1 QXQMENSTZKYZCE-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- XTRFZKJEMAVUIK-UHFFFAOYSA-N 2-[2,6-dichloro-4-(2,4,4-trimethylpentan-2-yl)phenoxy]acetic acid Chemical compound CC(C)(C)CC(C)(C)C1=CC(Cl)=C(OCC(O)=O)C(Cl)=C1 XTRFZKJEMAVUIK-UHFFFAOYSA-N 0.000 description 1
- CWWDSXQOEYQKQR-UHFFFAOYSA-N 2-[4-[4-(3-methyl-5-phenylpyrazol-1-yl)butyl]piperazin-1-yl]pyrimidine Chemical compound C1CN(C=2N=CC=CN=2)CCN1CCCCN1N=C(C)C=C1C1=CC=CC=C1 CWWDSXQOEYQKQR-UHFFFAOYSA-N 0.000 description 1
- JCZZBBKUFQLLIX-UHFFFAOYSA-N 2-[5-[4-(trifluoromethyl)phenyl]-1h-pyrazol-4-yl]pyrazine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=C(C=2N=CC=NC=2)C=NN1 JCZZBBKUFQLLIX-UHFFFAOYSA-N 0.000 description 1
- KUIFMGITZFDQMP-UHFFFAOYSA-N 2-amino-5-chlorobenzaldehyde Chemical compound NC1=CC=C(Cl)C=C1C=O KUIFMGITZFDQMP-UHFFFAOYSA-N 0.000 description 1
- DNRVZOZGQHHDAT-UHFFFAOYSA-N 2-amino-5-chlorobenzamide Chemical compound NC(=O)C1=CC(Cl)=CC=C1N DNRVZOZGQHHDAT-UHFFFAOYSA-N 0.000 description 1
- HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical compound NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- BMTSZVZQNMNPCT-UHFFFAOYSA-N 2-aminopyridin-3-ol Chemical compound NC1=NC=CC=C1O BMTSZVZQNMNPCT-UHFFFAOYSA-N 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- BSQLQMLFTHJVKS-UHFFFAOYSA-N 2-chloro-1,3-benzothiazole Chemical compound C1=CC=C2SC(Cl)=NC2=C1 BSQLQMLFTHJVKS-UHFFFAOYSA-N 0.000 description 1
- UJRMHFPTLFNSTA-UHFFFAOYSA-N 2-chloro-2,2-diphenylacetic acid Chemical compound C=1C=CC=CC=1C(Cl)(C(=O)O)C1=CC=CC=C1 UJRMHFPTLFNSTA-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- SHHKMWMIKILKQW-UHFFFAOYSA-N 2-formylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1C=O SHHKMWMIKILKQW-UHFFFAOYSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-M 2-iodobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-M 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- GPVOTFQILZVCFP-UHFFFAOYSA-N 2-trityloxyacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(=O)O)C1=CC=CC=C1 GPVOTFQILZVCFP-UHFFFAOYSA-N 0.000 description 1
- KKWRVUBDCJQHBZ-UHFFFAOYSA-N 3,4,5-trichloropyridine Chemical compound ClC1=CN=CC(Cl)=C1Cl KKWRVUBDCJQHBZ-UHFFFAOYSA-N 0.000 description 1
- WDNBURPWRNALGP-UHFFFAOYSA-N 3,4-Dichlorophenol Chemical compound OC1=CC=C(Cl)C(Cl)=C1 WDNBURPWRNALGP-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- RLBGJPGBPTUZRL-UHFFFAOYSA-N 3-(4-bromophenyl)-5-methylsulfonyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine Chemical compound C1=2CN(S(=O)(=O)C)CCC=2NN=C1C1=CC=C(Br)C=C1 RLBGJPGBPTUZRL-UHFFFAOYSA-N 0.000 description 1
- FVBMDOHBBQWMHA-UHFFFAOYSA-N 3-(4-chlorophenyl)-5-piperidin-4-yl-1,2,4-oxadiazole Chemical compound C1=CC(Cl)=CC=C1C1=NOC(C2CCNCC2)=N1 FVBMDOHBBQWMHA-UHFFFAOYSA-N 0.000 description 1
- ZZDDVUDBWCTPJV-UHFFFAOYSA-N 3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-1-yl]propanal Chemical compound C1N(S(=O)(=O)C)CCC(N(N=2)CCC=O)=C1C=2C1=CC=C(C(F)(F)F)C=C1 ZZDDVUDBWCTPJV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- INWUFXPCLZRSBH-UHFFFAOYSA-N 3-chloro-1,2-benzoxazole Chemical compound C1=CC=C2C(Cl)=NOC2=C1 INWUFXPCLZRSBH-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 150000000499 3-oxazolines Chemical class 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- UOQHRZYJHNODNL-UHFFFAOYSA-N 4,5-bis(methoxymethyl)-1,3-dioxolane Chemical compound COCC1OCOC1COC UOQHRZYJHNODNL-UHFFFAOYSA-N 0.000 description 1
- UBARRNXCKBFUEN-UHFFFAOYSA-N 4,5-diphenyl-5h-1,3-oxazol-2-one Chemical compound N=1C(=O)OC(C=2C=CC=CC=2)C=1C1=CC=CC=C1 UBARRNXCKBFUEN-UHFFFAOYSA-N 0.000 description 1
- NBJHDLKSWUDGJG-UHFFFAOYSA-N 4-(2-chloroethyl)morpholin-4-ium;chloride Chemical compound Cl.ClCCN1CCOCC1 NBJHDLKSWUDGJG-UHFFFAOYSA-N 0.000 description 1
- UXWLHPWCZJEEDL-UHFFFAOYSA-N 4-(2-nitrophenyl)-1,3-dioxolane Chemical compound [O-][N+](=O)C1=CC=CC=C1C1OCOC1 UXWLHPWCZJEEDL-UHFFFAOYSA-N 0.000 description 1
- NIQKXYRXMWKEKY-UHFFFAOYSA-N 4-(4-methoxyphenyl)-n-(3-morpholin-4-ium-4-ylpropyl)oxane-4-carboxamide;chloride Chemical compound Cl.C1=CC(OC)=CC=C1C1(C(=O)NCCCN2CCOCC2)CCOCC1 NIQKXYRXMWKEKY-UHFFFAOYSA-N 0.000 description 1
- BLAURXPHWHQJKX-UHFFFAOYSA-N 4-(bromomethyl)-1,3-dioxolane Chemical compound BrCC1COCO1 BLAURXPHWHQJKX-UHFFFAOYSA-N 0.000 description 1
- NDRAHSMAGKWWFZ-UHFFFAOYSA-N 4-(methylsulfanylmethoxy)butanoic acid Chemical compound CSCOCCCC(O)=O NDRAHSMAGKWWFZ-UHFFFAOYSA-N 0.000 description 1
- VDWBANLJTBKEOM-UHFFFAOYSA-N 4-(trifluoromethyl)thiophen-2-amine;hydrochloride Chemical compound Cl.NC1=CC(C(F)(F)F)=CS1 VDWBANLJTBKEOM-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- WAGMYTXJRVPMGW-UHFFFAOYSA-N 4-azidobutanoic acid Chemical compound OC(=O)CCCN=[N+]=[N-] WAGMYTXJRVPMGW-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- RJTDVQUMWKUFAK-UHFFFAOYSA-N 4-but-3-enyl-1,3-dioxolane Chemical compound C=CCCC1COCO1 RJTDVQUMWKUFAK-UHFFFAOYSA-N 0.000 description 1
- SQFLFRQWPBEDHM-UHFFFAOYSA-N 4-chloro-1-methyl-2-nitrobenzene Chemical compound CC1=CC=C(Cl)C=C1[N+]([O-])=O SQFLFRQWPBEDHM-UHFFFAOYSA-N 0.000 description 1
- PTCPUGKKWNMITF-UHFFFAOYSA-N 4-chloro-2-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1F PTCPUGKKWNMITF-UHFFFAOYSA-N 0.000 description 1
- NECBSSKNQDXVKN-UHFFFAOYSA-N 4-chloro-3-methylbenzoyl chloride Chemical compound CC1=CC(C(Cl)=O)=CC=C1Cl NECBSSKNQDXVKN-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 1
- KHKJLJHJTQRHSA-UHFFFAOYSA-N 4-methyl-4-nitropentanoic acid Chemical compound [O-][N+](=O)C(C)(C)CCC(O)=O KHKJLJHJTQRHSA-UHFFFAOYSA-N 0.000 description 1
- OVKDCYKVNYLEHK-UHFFFAOYSA-N 4-phenyl-1,3-dioxolane Chemical compound O1COCC1C1=CC=CC=C1 OVKDCYKVNYLEHK-UHFFFAOYSA-N 0.000 description 1
- NNJMFJSKMRYHSR-UHFFFAOYSA-M 4-phenylbenzoate Chemical compound C1=CC(C(=O)[O-])=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-M 0.000 description 1
- YFRNKLUVBCZXMJ-UHFFFAOYSA-N 4-piperidin-4-yl-1,4-benzoxazin-3-one Chemical compound O=C1COC2=CC=CC=C2N1C1CCNCC1 YFRNKLUVBCZXMJ-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- NTCIAFWCCFAZLW-UHFFFAOYSA-N 5,5-dibromo-1,3-dioxane Chemical compound BrC1(Br)COCOC1 NTCIAFWCCFAZLW-UHFFFAOYSA-N 0.000 description 1
- GRCMBNOFUBQBNT-UHFFFAOYSA-N 5-bromo-3-(2-chlorophenyl)-1-[4-(4-phenylpiperazin-1-yl)butyl]indazole Chemical compound ClC1=CC=CC=C1C(C1=CC(Br)=CC=C11)=NN1CCCCN1CCN(C=2C=CC=CC=2)CC1 GRCMBNOFUBQBNT-UHFFFAOYSA-N 0.000 description 1
- ZENPHNPMTCAFIG-UHFFFAOYSA-N 5-methyl-3-phenyl-1-[4-(4-phenylpiperazin-1-yl)butyl]indazole Chemical compound N1=C(C=2C=CC=CC=2)C2=CC(C)=CC=C2N1CCCCN(CC1)CCN1C1=CC=CC=C1 ZENPHNPMTCAFIG-UHFFFAOYSA-N 0.000 description 1
- JLECSPKJBGOVBW-UHFFFAOYSA-N 5-methylidene-1,3-dioxane Chemical compound C=C1COCOC1 JLECSPKJBGOVBW-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003133 Ambrosia artemisiifolia Nutrition 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- KPYSYYIEGFHWSV-QMMMGPOBSA-N Arbaclofen Chemical compound OC(=O)C[C@@H](CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-QMMMGPOBSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 description 1
- LBGABSUTBBBMBV-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](CC(CN(CC1)CCC1Oc(cc1Cl)ccc1Cl)O)nc2-c(cc1)cc(C)c1Cl)=O Chemical compound CC(N(CC1)Cc2c1[n](CC(CN(CC1)CCC1Oc(cc1Cl)ccc1Cl)O)nc2-c(cc1)cc(C)c1Cl)=O LBGABSUTBBBMBV-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940123003 Cathepsin inhibitor Drugs 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 241000238713 Dermatophagoides farinae Species 0.000 description 1
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000854908 Homo sapiens WD repeat-containing protein 11 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- FNJSWIPFHMKRAT-UHFFFAOYSA-N Monomethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(O)=O FNJSWIPFHMKRAT-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical class CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 229910017852 NH2NH2 Inorganic materials 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150087584 PPT1 gene Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004146 Propane-1,2-diol Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 108091005956 Type II transmembrane proteins Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 102100020705 WD repeat-containing protein 11 Human genes 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005585 adamantoate group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000005256 alkoxyacyl group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- KVPFKMBYCSISTN-UHFFFAOYSA-N benzylsulfanylformic acid Chemical compound OC(=O)SCC1=CC=CC=C1 KVPFKMBYCSISTN-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- CXNGYHAYLBTIPZ-UHFFFAOYSA-L bis(2,6-ditert-butyl-4-methylphenoxy)-methylalumane Chemical compound CC(C)(C)C=1C=C(C)C=C(C(C)(C)C)C=1O[Al](C)OC1=C(C(C)(C)C)C=C(C)C=C1C(C)(C)C CXNGYHAYLBTIPZ-UHFFFAOYSA-L 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 108010015574 cathepsin N Proteins 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical group S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 229940125693 central nervous system agent Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-M crotonate Chemical compound C\C=C\C([O-])=O LDHQCZJRKDOVOX-NSCUHMNNSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- GQQQULCEHJQUJT-UHFFFAOYSA-N ethyl 4-aminopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(N)CC1 GQQQULCEHJQUJT-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000004995 haloalkylthio group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- SXWRTZOXMUOJER-UHFFFAOYSA-N hydron;piperidin-4-one;chloride;hydrate Chemical compound O.Cl.O=C1CCNCC1 SXWRTZOXMUOJER-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-M methoxyacetate Chemical compound COCC([O-])=O RMIODHQZRUFFFF-UHFFFAOYSA-M 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- NYEBKUUITGFJAK-UHFFFAOYSA-N methylsulfanylmethanethioic s-acid Chemical compound CSC(O)=S NYEBKUUITGFJAK-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- ZKWFSTHEYLJLEL-UHFFFAOYSA-N morpholine-4-carboxamide Chemical compound NC(=O)N1CCOCC1 ZKWFSTHEYLJLEL-UHFFFAOYSA-N 0.000 description 1
- YUMYYTORLYHUFW-ZUDLOMHPSA-N morpholine-4-carboxylic acid (1-(3-benzenesulfonyl-1-phenethylallylcarbamoyl)-3-methylbutyl)-amide Chemical group N([C@H](CC(C)C)C(=O)N[C@H](CCC=1C=CC=CC=1)\C=C\S(=O)(=O)C=1C=CC=CC=1)C(=O)N1CCOCC1 YUMYYTORLYHUFW-ZUDLOMHPSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- GSMPSKWDIFSIAR-UHFFFAOYSA-N n-cyclohexyl-1-(4-nitrophenyl)methanimine Chemical compound C1=CC([N+](=O)[O-])=CC=C1C=NC1CCCCC1 GSMPSKWDIFSIAR-UHFFFAOYSA-N 0.000 description 1
- CBKFHSNATJJWQK-UHFFFAOYSA-N n-pyridin-3-ylformamide Chemical class O=CNC1=CC=CN=C1 CBKFHSNATJJWQK-UHFFFAOYSA-N 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 125000004971 nitroalkyl group Chemical group 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 150000002916 oxazoles Chemical class 0.000 description 1
- 150000002917 oxazolidines Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical compound OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 description 1
- FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical compound OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000002810 primary assay Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 150000005229 pyrazolopyridines Chemical class 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000009342 ragweed pollen Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- LOFZYSZWOLKUGE-UHFFFAOYSA-N s-benzyl carbamothioate Chemical compound NC(=O)SCC1=CC=CC=C1 LOFZYSZWOLKUGE-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 125000004963 sulfonylalkyl group Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DXPICDQAWKYSEQ-UHFFFAOYSA-N tert-butyl 4-(3-oxopyrido[3,2-b][1,4]oxazin-4-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C2=NC=CC=C2OCC1=O DXPICDQAWKYSEQ-UHFFFAOYSA-N 0.000 description 1
- VOKXZAXMWRVFNV-UHFFFAOYSA-N tert-butyl 4-(6-chloro-2,2-dioxo-3,4-dihydro-2$l^{6},1,3-benzothiadiazin-1-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1S(=O)(=O)NCC2=CC(Cl)=CC=C21 VOKXZAXMWRVFNV-UHFFFAOYSA-N 0.000 description 1
- HJWWWQKEEFTBMA-UHFFFAOYSA-N tert-butyl 4-(6-chloro-2-oxo-3,4-dihydroquinolin-1-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C2=CC=C(Cl)C=C2CCC1=O HJWWWQKEEFTBMA-UHFFFAOYSA-N 0.000 description 1
- YIACCSMJKKNDJI-UHFFFAOYSA-N tert-butyl 4-[3-(cyanomethyl)-2-oxobenzimidazol-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C(=O)N(CC#N)C2=CC=CC=C21 YIACCSMJKKNDJI-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- CPRPKIMXLHBUGA-UHFFFAOYSA-N triethyltin Chemical group CC[Sn](CC)CC CPRPKIMXLHBUGA-UHFFFAOYSA-N 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Definitions
- This invention relates to the use of a compound in the manufacture of a medicament for treating an allergic condition using substituted pyrazoles.
- Atopic allergies afflict at least 20% of populations in developed countries and comprise a wide range of IgE-mediated diseases such as hay fever, asthma, atopic dermatitis, and food allergies.
- Exposure of an allergic subject to relevant allergens cross-links allergen specific IgE bound to mast cells, triggering degranulation and release of proinflammatory mediators, such as histamine and eicosanoids, which cause the weal-and-flare response on a skin test. Characteristically, this early response is followed by a prolonged late reaction in which inflammatory cells, particularly eosinophils and activated TH-2 CD4 T cells, are recruited to the site of allergen exposure.
- Inflammatory cytokines such as IL-4 and IL-5, both produced by TH-2 cells, are important for IgE production by B cells and for eosinophilia, respectively.
- Immunotherapies targeting CD4 T cells have been shown to be effective in reducing the production of IgE, the activation of proinflammatory cells, and the release of inflammatory mediators.
- CD4 T cells The activation of CD4 T cells is a major factor in the initiation and maintenance of the allergic response. Allergens are taken up by specialized antigen presenting cells (APCs) such as dendritic cells and B cells. Protein allergens pass through the endosomal or lysosomal system where they are degraded by different proteases. These peptide fragments are bound by the MHC class II molecules which, at the cell surface, are heterotrimeric complexes consisting of two transmembrane glycoprotein chains ( ⁇ and ⁇ ) that form a binding scaffold for the third component, a peptide of 11-20 amino acids. The antigen-MHC class II molecule complex is recognized by CD4 T cells and leads to the activation of the T cell. Activated T cells in turn activate several other components of the immune system, such as B cells and macrophages, that are crucial for the body's response to pathogens, but also lead to the symptoms of allergies.
- APCs antigen presenting cells
- Class II molecules like other transmembrane proteins, are translocated into the endoplasmic reticulum (ER) after synthesis, where they associate with a third protein, the invariant chain (li).
- the invariant chain molecule is a type II transmembrane protein that serves as a class II-specific chaperone, promoting the exit of class II-li complexes from the ER and preventing class II molecules from binding to peptides and unfolded proteins in the ER and in the secretory pathway.
- a targeting motif in the cytoplasmic tail of li directs the class II-li complexes from the secretory pathway into the endosomal system.
- the li Before the MHC class II molecules can present antigen the li must be removed by a series of proteases that break down li.
- the resultant li peptide fragments called class II-associated invariant chain peptides (CLIP), occupy the peptide binding groove of the class II molecule, and in most cases are not spontaneously released.
- CLIP class II-associated invariant chain peptides
- the CLIP protects the class II binding pocket from collapsing both during intracellular transport and after li degradation in the endosomal system. Binding of antigenic peptides generated from endocytosed proteins requires an empty, and yet open binding site. The CLIP therefore must be released while the open binding site is stabilized to allow the binding of other peptides.
- Human Leukocyte Antigen - DM ('HLA-DM') mediates both of these functions, thus promoting the binding of antigenic peptides. After acquiring peptides, the class II molecules are transported to the cell surface via routes that are largely unknown.
- Cathepsin S ('CatS') is a cysteine protease expressed in lymphatic tissues. CatS mediates invariant chain proteolysis, which is a prerequisite for peptide loading of MHC class II molecules ( Riese et al. (1996) Immunity 4:357 ). CatS has 50-60% homology with cathepsins L and K, but differs from them in that it has a broad pH optimum that extends to alkaline pH. CatS modulates antigen presentation in animal models, and inhibitors are effective in an asthma model ( Riese et al. (1998) J. Clin. Invest. 101:2351 ).
- mice deficient in cathepsin S have an impaired ability to present exogenous proteins by professional antigen presenting cells ( Nakagawa et al. (1999) Immunity 10:207 ; Shi et al. (1999) Immunity 10:197 ).
- Compounds that inhibit the proteolytic activity of human cathepsin S are expected to find utility in the treatment of chronic autoimmune diseases including, but not limited to, lupus and rheumatoid arthritis; and have potential utility in modulating the immune response to tissue transplantation.
- Methods of modulating autoimmunity with an agent that modulates cathepsin S activity, e.g., proteolysis of the li chain, as well as methods of treating a subject having an autoimmune disorder, methods of evaluating a treatment for its ability to modulate an immune response are described in WO 99/58153 .
- EP-382637 describes pyrimidines having anxiolytic properties. This compound and analogs are further described in EP-502786 as cardiovascular and central nervous system agents. Pharmaceutical formulations with such compounds are disclosed in EP-655248 for use in the treatment of gastric secreation and as anti-ulcer agents.
- WO-9721439 describes medicaments with such compounds for treating obsessive-compulsive disorders, sleep apnea, sexual dysfunctions, emesis and motion sickness.
- EP 0 254 241 relates to the use and preparation of pyrazolopyridine compounds and their salts thereof.
- the compounds disclosed in this document are said to possess antiinflammatory, analgesic, antipyretic, antiallergic, antiarthritic, and antirheumatic activities.
- the compounds disclosed therein are said to posses inhibitory activities on platelet aggregation.
- the compounds 5-methyl-3-phenyl-1-[4-(4-phenyl-1-piperazinyl) butyl]-1H-indazole and 5-bromo-3-(2-chlorophenyl)-1-[4-(4-phenyl-1-piperazinyl) butyl]-1H-indazole, in particular the hydrochloride salts thereof, are known from WO-9853940 and CA 122:314528 , where these and similar compounds are described as kinase inhibitors in the former reference and possessing affinity for benzodiazepine receptors in the latter reference.
- the present invention features the use of cathepsin S inhibitors in the manufacture of a pharmaceutical composition to treat allergic conditions, including but not limited to atopic allergies.
- allergic conditions including but not limited to atopic allergies.
- Examples of an allergic condition include hay fever, asthma, atopic dermatitis and food allergies. Allergens include dust, pollen, mold, and pet dander or pet hair.
- the invention provides the use of a compound in the manufacture of a pharmaceutical composition for treating a subject suffering from an allergic condition, in particular an atopic allergic condition, said compound being of formula I as shown in claim 1.
- the invention provides the use of a compound in the manufacture of a pharmaceutical composition for treating a subject suffering from an IgE-mediated allergic condition, in particular an atopic allergic condition, said compound being of formula I as shown in claim 1.
- a third aspect of the invention provides the use, or the use for the manufacture of a medicament, of a cathepsin S inhibitor for treating an allergic condition, more in particular for treating IgE-mediated allergic conditions, still more in particular treating hay fever, asthma, atopic dermatitis or food allergies.
- the invention also features anti-allergic pharmaceutical compositions comprising as active ingredient an effective amount of a cathepsin S inhibitor, and a pharmaceutically acceptable carrier.
- the active ingredient can be formulated in any manner suitable for the particular allergic condition, including aerosol, oral and topical formulations and time-release formulations.
- the present invention concerns the use of a pharmaceutical composition for the treatment of an allergic condition using one or more compounds which can be represented by formula (I): wherein:
- One embodiment of the invention is the use of a compound in the manufacture of a medicament for the treatment of an allergic condition using a compound of formula(I), wherein Ar 2 is selected from 5-7 membered monocyclic rings, and [5,6], [6,6], [6,5], and [5,5] fused bicyclic ring systems, said ring or ring system being carbocyclic or heterocyclic, saturated, unsaturated, or aromatic, optionally substituted with halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, nitro, hydroxy, amino, mono- or di-(C 1-6 alkyl)amino, C 1-4 alkoxy, C 2-4 alkoxycarbonyl, C 2-6 acyl, C 2-6 acyloxy, C 1-5 alkylsulfonyl, C 1-5 alkoxycarbonylC 1-4 alkoxy, cyano, and mono- or di-(C 1-6 alkyl)carbamoyl.
- Another embodiment of the invention is the use of a compound of formula (I), wherein Ar 2 is selected from 2,5-di(C 1-6 alkyl)aminopyrrolyl and the following 6 formulae: wherein
- the disclosed compounds are high-affinity inhibitors of the proteolytic activity of human cathepsin S.
- the preparation of pharmaceutically acceptable salts of compounds of formula (I) may be desirable.
- Certain compounds of the present invention may have one stereogenic atom and may exist as two enantiomers. Certain compounds of the present invention may have two or more stereogenic atoms and may further exist as diastereomers. It is to be understood by those skilled in the art that all such stereoisomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
- Another aspect of the invention provides pharmaceutical anti-allergic compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
- a further embodiment of the invention is a process for making a pharmaceutical anti-allergic composition comprising mixing a disclosed compound as described above, with a suitable pharmaceutically acceptable carrier.
- compositions comprising more than one compound of formula (I) and compositions comprising a compound of formula (I) and another pharmaceutically active agent.
- the invention features the use of a compound in the manufacture of a pharmaceutical composition of treating allergic disorders or conditions mediated by the cathepsin S enzyme, in a subject in need thereof, comprising any of the compounds or pharmaceutical compositions described above.
- the compounds described herein inhibit the protease activity of human cathepsin S, an enzyme involved in the immune response. In preferred embodiments, cathepsin S inhibition is selective.
- a target of the present invention was to determine whether the presentation of particular antigens in a human system is affected by the inhibition of cathepsin S. According to the invention, it now has been found that inhibitors of cathepsin S block the presentation of several crude allergen extracts in a human ex vivo assay, thereby supporting the use of cathepsin S inhibitors in the manufacture of a pharmaceutical composition for the treatment of allergic conditions.
- Blocking li degradation should decrease antigen presentation to CD4 T cells and disrupt the normal immune response.
- a cathepsin S inhibitor should specfically affect the activation of CD4 T cells, thus limiting the extent of concomitant immunosuppression, an undesirable side effect of corticosteroid therapy.
- the immunological component of the allergic reaction can be blocked to varying degrees, with the advantage over current therapies of being more selective, having fewer or reduced side effects, or both.
- the present invention is based, in part, on the finding that cathepsin S inhibitors can block the presentation of crude allergen extracts in a human ex vivo assay. This ex vivo system closely mimics the process that occurs in the whole body wherein antigens enter the blood stream,and are presented by antigen presenting cells, which in turn activate CD4 T cells. In the case of treating a subject, the inhibitor or a metabolite thereof would also be present in the blood as in the ex vivo assay.
- the invention features the manufacture of a pharmaceutical composition for the treatment of an allergic condition using one or more pyrazole compounds of formula (I).
- Alkyl includes optionally substituted straight chain and branched hydrocarbons with at least one hydrogen removed to form a radical group.
- Alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, 1-methylpropyl, pentyl, isopentyl, sec-pentyl, hexyl, heptyl, octyl, and so on.
- Alkyl includes cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- Alkenyl includes optionally substituted straight chain and branched hydrocarbon radicals as above with at least one carbon-carbon double bond (sp 2 ).
- Alkenyls include ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl), isopropenyl (or 1-methylvinyl), but-1-enyl, but-2-enyl, butadienyls, pentenyls, hexa-2,4-dienyl, and so on.
- Hydrocarbon radicals having a mixture of double bonds and triple bonds, such as 2-penten-4-ynyl, are grouped as alkynyls herein.
- Alkenyl includes cycloalkenyl. Cis and trans or (E) and (Z) forms are included within the invention.
- Alkynyl includes optionally substituted straight chain and branched hydrocarbon radicals as above with at least one carbon-carbon triple bond (sp).
- Alkynyls include ethynyl, propynyls, butynyls, and pentynyls.
- Hydrocarbon radicals having a mixture of double bonds and triple bonds, such as 2-penten-4-ynyl, are grouped as alkynyls herein.
- Alkynyl does not include cycloalkynyl.
- Alkoxy includes an optionally substituted straight chain or branched alkyl group with a terminal oxygen linking the alkyl group to the rest of the molecule.
- Alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and so on.
- Aminoalkyl”, “thioalkyl”, and “sulfonylalkyl” are analogous to alkoxy, replacing the terminal oxygen atom of alkoxy with, respectively, NH (or NR), S, and SO 2 .
- Heteroalkyl includes alkoxy, aminoalkyl, thioalkyl, and so on.
- Aryl includes phenyl, naphthyl, biphenylyl, tetrahydronaphthyl, and so on, any of which may be optionally substituted.
- Aryl also includes arylalkyl groups such as benzyl, phenethyl, and phenylpropyl.
- Aryl includes a ring system containing an optionally substituted 6-membered carbocyclic aromatic ring, said system may be bicyclic, bridge, and/or fused. The system may include rings that are aromatic, or partially or completely saturated.
- ring systems include indenyl, pentalenyl, 1-4-dihydronaphthyl, indanyl, benzimidazolyl, benzothiophenyl, indolyl, benzofuranyl, isoquinolinyl, and so on.
- Heterocyclyl includes optionally substituted aromatic and nonaromatic rings having carbon atoms and at least one heteroatom (O, S, N) or heteroatom moiety (SO 2 , CO, CONH, COO) in the ring.
- a heterocyclic radical may have a valence connecting it to the rest of the molecule through a carbon atom, such as 3-furyl or 2-imidazolyl, or through a heteroatom, such as N-piperidyl or 1-pyrazolyl.
- a monocyclic heterocyclyl has between 4 and 7 ring atoms, or between 5 and 6 ring atoms; there may be between 1 and 5 heteroatoms or heteroatom moieties in the ring, and preferably between 1 and 3.
- a heterocyclyl may be saturated, unsaturated, aromatic (e.g., heteroaryl), nonaromatic, or fused.
- Heterocyclyl also includes fused, e.g., bicyclic, rings, such as those optionally condensed with an optionally substituted carbocyclic or heterocyclic five- or six-membered aromatic ring.
- heteroaryl includes an optionally substituted six-membered heteroaromatic ring containing 1, 2 or 3 nitrogen atoms condensed with an optionally substituted five- or six-membered carbocyclic or heterocyclic aromatic ring.
- Said heterocyclic five- or six-membered aromatic ring condensed with the said five- or six-membered aromatic ring may contain 1, 2 or 3 nitrogen atoms where it is a six-membered ring, or 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur where it is a five-membered ring.
- heterocyclyls include thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl.
- heterocyclyls or heterocyclic radicals include morpholinyl, piperazinyl, pyrrolidinyl, pyridyl, cyclohexylimino, cycloheptylimino, and more preferably, piperidyl.
- heteroaryl examples include thienyl, furanyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, benzothienyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothiazolyl.
- Acyl refers to a carbonyl moiety attached to either a hydrogen atom (i.e., a formyl group) or to an optionally substituted alkyl or alkenyl chain, or heterocyclyl.
- Halo or “halogen” includes fluoro, chloro, bromo, and iodo, and preferably chloro or bromo as a substituent.
- Alkanediyl or "alkylene” represents straight or branched chain optionally substituted bivalent alkane radicals such as, for example, methylene, ethylene, propylene, butylene, pentylene or hexylene.
- Alkenediyl represents, analogous to the above, straight or branched chain optionally substituted bivalent alkene radicals such as, for example, propenylene, butenylene, pentenylene or hexenylene. In such radicals, the carbon atom linking a nitrogen preferably should not be unsaturated.
- Aroyl refers to a carbonyl moiety attached to an optionally substituted aryl or heteroaryl group, wherein aryl and heteroaryl have the definitions provided above.
- benzoyl is phenylcarbonyl.
- two radicals, together with the atom(s) to which they are attached may form an optionally substituted 4- to 7-, 5 - to 7-, or a 5- to 6-membered ring carbocyclic or heterocyclic ring, which ring may be saturated, unsaturated or aromatic.
- Said rings may be as defined above in the Summary of the Invention section. Particular examples of such rings are as follows in the next section.
- “Pharmaceutically acceptable salts, esters, and amides” include carboxylate salts (e.g., C 1-8 alkyl, cycloalkyl, aryl, heteroaryl, or non-aromatic heterocyclic) amino acid addition salts, esters, and amides which are within a reasonable benefit/risk ratio, pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response.
- Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, and laurylsulfonate.
- alkali metal and alkali earth cations such as sodium, potassium, calcium, and magnesium, as well as non-toxic ammonium, quaternary ammonium, and amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine.
- alkali metal and alkali earth cations such as sodium, potassium, calcium, and magnesium
- non-toxic ammonium, quaternary ammonium, and amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine.
- amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine.
- Representative pharmaceutically acceptable amides of the invention include those derived from ammonia, primary C 1-6 alkyl amines and secondary di (C 1-6 alkyl) amines.
- Secondary amines include 5- or 6-membered heterocyclic or heteroaromatic ring moieties containing at least one nitrogen atom and optionally between 1 and 2 additional heteroatoms.
- Preferred amides are derived from ammonia, C 1-3 alkyl primary amines, and di (C 1-2 alkyl)amines.
- Representative pharmaceutically acceptable esters of the invention include C 1-7 alkyl, C 5-7 cycloalkyl, phenyl, and phenyl(C 1-6 )alkyl esters.
- Preferred esters include methyl esters.
- Patient or subject includes mammals such as humans and animals (dogs, cats, horses, rats, rabbits, mice, non-human primates) in need of observation, experiment, treatment or prevention in connection with the relevant disease or condition.
- the patient or subject is a human.
- Composition includes a product comprising the specified ingredients in the specified amounts as well as any product which results directly or indirectly from combinations of the specified ingredients in the specified amounts.
- “Therapeutically effective amount” or “effective amount” means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
- each radical includes substituted radicals of that type and monovalent, bivalent, and multivalent radicals as indicated by the context of the claims.
- the context will indicate that the substituent is an alkylene or hydrocarbon radical with at least two hydrogen atoms removed (bivalent) or more hydrogen atoms removed (multivalent).
- An example of a bivalent radical linking two parts of the molecule is G in formula (I) which links two rings.
- radicals or structure fragments as defined herein are understood to include substituted radicals or structure fragments.
- Hydrocarbyls include monovalent radicals containing carbon and hydrogen such as alkyl, alkenyl, alkynyl, cycloalkyl, and cycloalkenyl (whether aromatic or unsaturated), as well as corresponding divalent radicals such as alkylene, alkenylene, phenylene, and so on.
- Heterocarbyls include monovalent and divalent radicals containing carbon, hydrogen, and at least one heteroatom. Examples of monovalent heterocarbyls include acyl, acyloxy, alkoxyacyl, heterocyclyl, heteroaryl, aroyl, benzoyl, dialkylamino, hydroxyalkyl, and so on.
- alkyl should be understood to include substituted alkyl having one or more substitutions, such as between 1 and 5, 1 and 3, or 2 and 4 substituents.
- the substituents may be the same (dihydroxy, dimethyl), similar (chlorofluoro), or different (chlorobenzyl- or aminomethyl-substituted).
- substituted alkyl examples include haloalkyl (such as fluoromethyl, chloromethyl, difluoromethyl, perchloromethyl, 2-bromoethyl, perfluoromethyl, and 3-iodocyclopentyl), hydroxyalkyl (such as hydroxymethyl, hydroxyethyl, 2-hydroxypropyl, aminoalkyl (such as aminomethyl, 2-aminoethyl, 3-aminopropyl, and 2-aminopropyl), nitroalkyl, alkylalkyl, and so on.
- haloalkyl such as fluoromethyl, chloromethyl, difluoromethyl, perchloromethyl, 2-bromoethyl, perfluoromethyl, and 3-iodocyclopentyl
- hydroxyalkyl such as hydroxymethyl, hydroxyethyl, 2-hydroxypropyl
- aminoalkyl such as aminomethyl, 2-aminoethyl, 3-aminopropyl, and 2-
- a di(C 1-6 alkyl)amino group includes independently selected alkyl groups, to form, for example, methylpropylamino and isopropylmethylamino, in addition dialkylamino groups having two of the same alkyl group such as dimethyl amino or diethylamino.
- Preferred substitutions for Ar or Ar 1 include methyl, methoxy, fluoromethyl, difluoromethyl, perfluoromethyl (trifluoromethyl), 1-fluoroethyl, 2-fluoroethyl, ethoxy, fluoro, chloro, and bromo, and particularly methyl, bromo, chloro, perfluoromethyl, perfluoromethoxy, methoxy, and fluoro.
- Preferred substitution patterns for Ar or Ar 1 are 4-substituted or 3,4-disubstituted phenyl.
- the invention features the treatment of an allergic condition with one or more compounds of formula (I) as described in the Summary section.
- Preferred compounds include those wherein:
- preferred compounds include those wherein Ar or Ar 1 is selected from 4-trifluoromethylphenyl, 4-bromophenyl, 4-chlorophenyl, 4-chloro-3-methylphenyl and 3,4-dichlorophenyl. More preferred compounds include Examples 37 and 50.
- the invention provides the disclosed compounds and closely related, pharmaceutically acceptable forms of the disclosed compounds, such as salts, esters, amides, acids, hydrates or solvated forms thereof; masked or protected forms; and racemic mixtures, or enantiomerically or optically pure forms.
- Related compounds also include compounds of the invention that have been modified to be detectable, e.g., isotopically labelled with 18 F for use as a probe in positron emission tomography (PET) or single-photon emission computed tomography (SPECT).
- the invention also includes disclosed compounds having one or more functional groups (e.g., hydroxyl, amino, or carboxyl) masked by a protecting group. See, e.g., Greene and Wuts, Protective Groups in Organic Synthesis, 3rd ed., (1999) John Wiley & Sons, NY . Some of these masked or protected compounds are pharmaceutically acceptable; others will be useful as intermediates. Synthetic intermediates and processes disclosed herein, and minor modifications thereof, are also within the scope of the invention.
- Protection for the hydroxyl group includes methyl ethers, substituted methyl ethers, substituted ethyl ethers, substitute benzyl ethers, and silyl ethers.
- substituted methyl ethers include methyoxymethyl, methylthiomethyl, t -butylthiomethyl, (phenyldimethylsilyl)methoxymethyl, benzyloxymethyl, p -methoxybenzyloxymethyl, (4-methoxyphenoxy)methyl, guaiacolmethyl, t -butoxymethyl, 4-pentenyloxymethyl, siloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl, tetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl, 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxido, 1-[(2-chlor
- substituted ethyl ethers include 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t- butyl, allyl, p- chlorophenyl, p- methoxyphenyl, 2,4-dinitrophenyl, and benzyl.
- substituted benzyl ethers include p -methoxybenzyl, 3,4-dimethoxybenzyl, o -nitrobenzyl, p -nitrobenzyl, p -halobenzyl, 2,6-dichlorobenzyl, p -cyanobenzyl, p -phenylbenzyl, 2- and 4-picolyl, 3-methyl-2-picolyl N-oxido, diphenylmethyl, p , p '-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, ⁇ -naphthyldiphenylmethyl, p- methoxyphenyldiphenylmethyl, di( p- methoxyphenyl)phenylmethyl, tri( p- methoxyphenyl)methyl, 4-(4'-bromophenacyloxy)phenyldiphenylmethyl, 4,4',4"-tris(4,5-dichlorophthalimid
- silyl ethers examples include trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylthexylsilyl, t- butyldimethylsilyl, t- butyldiphenylsilyl, tribenzylsilyl, tri- p- xylylsilyl, triphenylsilyl, diphenylmethylsilyl, and t- butylmethoxyphenylsilyl.
- esters include formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p- chlorophenoxyacetate, p- P-phenylacetate, 3-phenylpropionate, 4-oxopentanoate(levulinate), 4,4-(ethylenedithio)pentanoate, pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p- phenylbenzoate, 2,4,6-trimethylbenzoate(mesitoate)
- carbonate protecting groups include methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, 2-(triphenylphosphonio)ethyl, isobutyl, vinyl, allyl, p- nitrophenyl, benzyl, p -methoxybenzyl, 3,4-dimethoxybenzyl, o- nitrobenzyl, p- nitrobenzyl, S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl, and methyl dithiocarbonate.
- assisted cleavage examples include 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o- (dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl carbonate, 4-(methylthiomethoxy)butyrate, and 2-(methylthiomethoxymethyl)benzoate.
- miscellaneous esters examples include 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate(tigloate), o -(methoxycarbonyl)benzoate, p- P-benzoate, ⁇ -naphthoate, nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate, N-phenylcarbamate, borate, dimethylphosphinothioyl, and 2,4-dinitrophenylsulfenate.
- sulfonates include sulfate, methanesulfonate(mesylate), benzylsulfonate, and tosylate.
- Protection for the amino group includes carbamates, amides, and special -NH protective groups.
- carbamates examples include methyl and ethyl carbamates, substituted ethyl carbamates, assisted cleavage carbamates, photolytic cleavage carbamates, urea-type derivatives, and miscellaneous carbamates.
- methyl and ethyl carbamates include methyl and ethyl, 9-fluorenylmethyl, 9-(2-sulfo)fluorenylmethyl, 9-(2,7-dibromo)fluorenylmethyl, 2,7-di- t- butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl, and 4-methoxyphenacyl.
- substituted ethyl carbamates examples include 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-phenylethyl, 1-(1-adamantyl)-1-methylethyl, 1,1-dimethyl-2-haloethyl, 1,1-dimethyl-2,2-dibromoethyl, 1,1-dimethyl-2,2,2-trichloroethyl, 1-methyl-1-(4-biphenylyl)ethyl, 1-(3,5-di- t -butylphenyl)-1-methylethyl, 2-(2'- and 4'-pyridyl)ethyl, 2-(N,N-dicyclohexylcarboxamido)ethyl, t- butyl, 1-adamantyl, vinyl, allyl, 1-isopropylallyl, cinnamyl, 4-nitrocinnamyl, 8-quinolyl, N
- assisted cleavage examples include 2-methylthioethyl, 2-methylsulfonylethyl, 2-( p- toluenesulfonyl)ethyl, [2-(1,3-dithianyl)]methyl, 4-methylthiophenyl, 2,4-dimethylthiophenyl, 2-phosphonioethyl, 2-triphenylphosphonioisopropyl, 1,1-dimethyl-2-cyanoethyl, m -chloro- p- acyloxybenzyl, p- (dihydroxyboryl)benzyl, 5-benzisoxazolylmethyl, and 2-(trifluoromethyl)-6-chromonylmethyl.
- photolytic cleavage examples include m- nitrophenyl, 3,5-dimethoxybenzyl, o- nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, and phenyl( o- nitrophenyl)methyl.
- urea-type derivatives include phenothiazinyl-(10)-carbonyl derivative, N' - p- toluenesulfonylaminocarbonyl, and N'-phenylaminothiocarbonyl.
- miscellaneous carbamates include t- amyl, S-benzyl thiocarbamate, p- cyanobenzyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropylmethyl, p- decyloxybenzyl, diisopropylmethyl, 2,2-dimethoxycarbonylvinyl, o- (N,N-dimethylcarboxamido)benzyl, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl, 1,1-dimethylpropynyl, di(2-pyridyl)methyl, 2-furanylmethyl, 2-iodoethyl, isobomyl, isobutyl, isonicotinyl, p- ( p'- methoxyphenylazo)benzyl, 1-methylcyclobutyl, 1-methylcyclohexyl, 1-methyl-1-cyclopropyl
- amides examples include:
- N-formyl N-acetyl, N-chloroacetyl, N-trichloroacetyl, N-trifluoroacetyl, N-phenylacetyl, N-3-phenylpropionyl, N-picolinoyl, N-3-pyridylcarboxamide, N-benzoylphenylalanyl derivative, N-benzoyl, N- p- phenylbenzoyl.
- N-phthalimide N-dithiasuccinoyl, N-2,3-diphenylmaleoyl, N-2,5-dimethylpyrrolyl, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct, 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, and 1-substituted 3,5-dinitro-4-pyridonyl.
- acyclic acetals and ketals examples include dimethyl, bis(2,2,2-trichloroethyl), dibenzyl, bis(2-nitrobenzyl) and diacetyl.
- Examples of cyclic acetals and ketals include 1,3-dioxanes, 5-methylene-1,3-dioxane, 5,5-dibromo-1,3-dioxane, 5-(2-pyridyl)-1,3-dioxane, 1,3-dioxolanes, 4-bromomethyl-1,3-dioxolane, 4-(3-butenyl)-1,3-dioxolane, 4-phenyl-1,3-dioxolane, 4-(2-nitrophenyl)-1,3-dioxolane, 4,5-dimethoxymethyl-1,3-dioxolane, O,O' -phenylenedioxy and 1,5-dihydro-3H-2,4-benzodioxepin.
- cyclic dithio acetals and ketals examples include S,S'-dimethyl, S,S'-diethyl, S,S'-dipropyl, S,S'-dibutyl, S,S'-dipentyl, S,S'-diphenyl, S,S'-dibenzyl and S,S'-diacetyl.
- cyclic dithio acetals and ketals examples include 1,3-dithiane, 1,3-dithiolane and 1,5-dihydro-3H-2,4-benzodithiepin.
- cyclic monothio acetals and ketals examples include O- trimethylsilyl-S-alkyl, O- methyl-S-alkyl or -S-phenyl and O- methyl-S-2-(methylthio)ethyl.
- cyclic monothio acetals and ketals examples include 1,3-oxathiolanes.
- O- substituted cyanohydrins examples include O- acetyl, O- trimethylsilyl, O- 1-ethoxyethyl and O- tetrahydropyranyl.
- substituted hydrazones include N,N-dimethyl and 2,4-dinitrophenyl.
- oxime derivatives include O- methyl, O- benzyl and O- phenylthiomethyl.
- substituted methylene and cyclic derivatives examples include oxazolidines, 1-methyl-2-(1'-hydroxyalkyl)imidazoles, N,N'-dimethylimidazolidines, 2,3-dihydro-1,3-benzothiazoles, diethylamine adducts, and methylaluminum bis(2,6-di- t- butyl-4-methylphenoxide)(MAD)complex.
- substituted methyl esters include 9-fluorenylmethyl, methoxymethyl, methylthiomethyl, tetrahydropyranyl, tetrahydrofuranyl, methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzyloxymethyl, phenacyl, p- bromophenacyl, ⁇ -methylphenacyl, p- methoxyphenacyl, carboxamidomethyl, and N-phthalimidomethyl.
- 2-substituted ethyl esters examples include 2,2,2-trichloroethyl, 2-haloethyl, ⁇ -chloroalkyl, 2-(trimethylsilyl)ethyl, 2-methylthioethyl, 1,3-dithianyl-2-methyl, 2-( p- nitrophenylsulfenyl)ethyl, 2-( p- toluenesulfonyl)ethyl, 2-(2'-pyridyl)ethyl, 2-(diphenylphosphino)ethyl, 1-methyl-1-phenylethyl, t- butyl, cyclopentyl, cyclohexyl, allyl, 3-buten-1-yl, 4-(trimethylsilyl)-2-buten-1-yl, cinnamyl, ⁇ -methylcinnamyl, phenyl, p- (methylmercapto)phenyl and benz
- substituted benzyl esters include triphenylmethyl, diphenylmethyl, bis( o- nitrophenyl)methyl, 9-anthrylmethyl, 2-(9,10-dioxo)anthrylmethyl, 5-dibenzosuberyl, 1-pyrenylmethyl, 2-(trifluoromethyl)-6-chromylmethyl, 2,4,6-trimethylbenzyl, p- bromobenzyl, o- nitrobenzyl, p- nitrobenzyl, p- methoxybenzyl, 2,6-dimethoxybenzyl, 4-(methylsulfinyl)benzyl, 4-sulfobenzyl, piperonyl, 4-picolyl and p- P-benzyl.
- silyl esters examples include trimethylsilyl, triethylsilyl, t- butyldimethylsilyl, i -propyldimethylsilyl, phenyldimethylsilyl and di- t butylmethylsilyl.
- activated esters include thiols.
- miscellaneous derivatives include oxazoles, 2-alkyl-1,3-oxazolines, 4-alkyl-5-oxo-1,3-oxazolidines, 5-alkyl-4-oxo-1,3-dioxolanes, ortho esters, phenyl group and pentaaminocobalt(III) complex.
- stannyl esters examples include triethylstannyl and tri-n-butylstannyl.
- amides include N,N-dimethyl, pyrrolidinyl, piperidinyl, 5,6-dihydrophenanthridinyl, o- nitroanilides, N-7-nitroindolyl, N-8-Nitro-1,2,3,4-tetrahydroquinolyl, and p- P-benzenesulfonamides.
- hydrazides examples include N-phenyl and N,N'-diisopropyl hydrazides.
- the compounds of the present invention may be prepared by conventional synthetic organic chemistry and by matrix or combinatorial methods according to Schemes 1 to 10 below, and Examples 1 to 31. Those of ordinary skill in the art will be able to modify and adapt the guidance provided herein to make the disclosed compounds.
- the present compounds inhibit the proteolytic activity of human cathepsin S and therefore are useful as a medicine especially in the manufacture of a pharmaceutical composition for treating patients suffering from allergic disorders or conditions which are modulated or regulated by the inhibition of cathepsin S activity.
- the invention features the use of a compound in the manufacture of a pharmaceutical composition for treating a subject with an allergic condition mediated by cathepsin S, said compound being of formula I as shown in claim 1.
- the invention also provides the use of a compound in the manufacture of a pharmaceutical composition for inhibiting cathepsin S activity in a subject, wherein the compound is of formula I as shown in claim 1.
- the compounds of the present invention may be formulated into various pharmaceutical forms for administration purposes.
- an effective amount of a particular compound, in base or acid addition salt form, as the active ingredient is intimately mixed with a pharmaceutically acceptable carrier.
- a carrier may take a wide variety of forms depending on the form of preparation desired for administration.
- These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for oral administration or parenteral injection.
- any of the usual pharmaceutical media may be employed. These include water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets.
- tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are generally employed.
- the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
- injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
- injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
- the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Such additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
- compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.
- Acid addition salts of the compounds of formula I due to their increased water solubility over the corresponding base form, are more suitable in the preparation of aqueous compositions.
- Dosage unit form as used in the specification herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
- Pharmaceutically acceptable acid addition salts include the therapeutically active non-toxic acid addition salt forms which the disclosed compounds are able to form. The latter can conveniently be obtained by treating the base form with an appropriate acid.
- Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g.
- hydrochloric or hydrobromic acid sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p- toluenesulfonic, cyclamic, salicylic, p- aminosalicylic, palmoic and the like acids.
- the term addition salt also comprises the solvates which the disclosed componds, as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like. Conversely the salt form can be converted by treatment with alkali into the free base form.
- Stereoisomeric form defines all the possible isomeric forms which the compounds of formula (I) may possess.
- the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. More in particular, stereogenic centers may have the (R)- or (S)-configuration; substituents on bivalent cyclic saturated radicals may have either the cis- or trans-configuration.
- the invention encompasses stereochemically isomeric forms including diastereoisomers, as well as mixtures thereof in any proportion of the disclosed compounds.
- the disclosed compounds may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above and following formulae are intended to be included within the scope of the present invention.
- a therapeutically effective dose would be from 0.001 mg/kg to 5 mg/kg body weight, more preferably from 0.01 mg/kg to 0.5 mg/kg body weight. It may be appropriate to administer the therapeutically effective dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.05 mg to 250 mg, and in particular 0.5 to 50 mg of active ingredient per unit dosage form. Examples include 2 mg, 4 mg, 7 mg, 10 mg, 15 mg, 25 mg, and 35 mg dosage forms. Compounds of the invention may also be prepared in time-release or subcutaneous or transdermal patch formulations. Disclosed compound may also be formulated as a spray or other topical or inhalable formulations.
- the exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the patient may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated patient and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned herein are therefore only guidelines.
- the next section includes detailed information relating to the preparation, characterization, and use of the disclosed compounds.
- the aqueous phase was extracted with CHCl 3 (2 x 10 mL) and the combined organic extracts were dried over Na 2 SO 4 and the solvent was removed under reduced pressure.
- the crude material was then diluted with Ac 2 O (3.0 mL) and was stirred for 48 h. The solvent was removed under reduced pressure and the crude material was pumped down overnight. The resulting solid was dissolved in MeOH (5.0 mL) and a catalytic amount (0.05 g) of K 2 CO 3 was added to the mixture and stirring was continued overnight.
- the reaction was then diluted with H 2 O (20 mL) and CH 2 Cl 2 (20 mL) and the layers were separated.
- the reaction mixture was stirred at 25 °C for 24 h and diluted with aqueous HCl (5%, 25 mL). After stirring for another 30 min, the organic layer was separated, washed with H 2 O (20 mL), dried (Na 2 SO 4 ), and concentrated. The residue was dissolved in EtOH (95%, 18 mL) and treated at 0 °C with hydrazine (2.9 mL, 60 mmol). The mixture was stirred at 25°C for 3 h and H 2 O (4 mL) was added. Most of the volatiles were removed and the residue extracted with CH 2 Cl 2 (50 mL). The organic layer was separated, washed with H 2 O (20 mL), dried over Na 2 SO 4 , and concentrated.
- the aqueous layer was extracted with CH 2 Cl 2 (2 x 25 mL) and the combined organic layers were washed with brine, dried over Na 2 SO 4 , and the solvent was removed under reduced pressure.
- the crude solid was diluted with CH 2 Cl 2 (15 mL) and 0.89 g (5.51 mmol) of carbonyldiimidazole was added in one portion and mixture was stirred for 16 h.
- the mixture was diluted with CH 2 Cl 2 (50 mL) and 1 N HCl (50 mL) and the layers were separated.
- the aqueous layer was extracted with CH 2 Cl 2 (2 x 25 mL) and the combined organic layers were washed with brine, dried over Na 2 SO 4 , and the solvent was removed under reduced pressure.
- the eneamine was divided and 320 g (1.19 mol) was diluted with CH 2 Cl 2 (1.0 L) and 165.0 mL (1.19 mol) of Et 3 N was added. The mixture was cooled to 0 °C and a solution of 225 g (1.08 mol) of 4-trifluoromethylbenzoyl chloride in CH 2 Cl 2 (0.5 L) was added slowly by dropping funnel over 1h. The mixture was allowed to warm to rt and stir overnight. The reaction was then diluted with 1 N HCl (450 mL) and stirred vigorously for 3h. The aqueous layer was extracted with CH 2 Cl 2 (3 x 500 mL) and the combined extracts were dried over Na 2 SO 4 and the solvent was removed under reduced pressure.
- Potassium carbonate (324 g, 2340 mmol) was added to a solution of 4-piperidone monohydrate hydrochloride (90 g, 586 mmol) in chloroform (300 mL) and water (300 mL).
- the slurry was cooled to 0 °C and treated with methylsulfonyl chloride (136 mL, 1760 mmol) by dropwise addition over a 1 h period.
- the reaction mixture was allowed to shake for 72 h and was partitioned between CH 2 Cl 2 (500 mL) and saturated aqueous NaHCO 3 (500 mL). The aqueous layer was extracted with CH 2 Cl 2 (3 X 200 mL).
- the precipitated material was filtered out and washed with water (4 X 100 mL) and dried in a Freeze Drying System.
- the crude material (31.0 g) was taken up in anhydrous DMF (65 mL) and Cs 2 CO 3 (33.74 g, 103.5 mmol) was added, and stirred for 10 min.
- 3-Bromo-1-propanol (8.6 mL, 13.2 g, 94.9 mmol) and MeOH (6.0 mL, 4.75 g, 148 mmol) were added and stirring continued under N 2 at rt for 15 h.
- Water 500 mL was added to the reaction and stirred for 10 min.
- the precipitated material was filtered and washed with water (3 X 100 mL).
- Methyl 2-aminophenylacetate (3.0 g, 18.2 mmol) and 1- tert -butoxycarbonyl-4-piperidone (4.5 g, 22.6 mmol) were set stirring in 50 mL of CH 2 Cl 2 under an atmosphere of nitrogen.
- Sodium triacetoxyborohydride (5.4 g, 25.5 mmol) was added followed by 1 mL of acetic acid. After 20 h at rt the mixture was quenched by the slow addition of saturated NaHCO 3 . After stirring for 30 min, the organics were separated, dried (MgSO 4 ), and evaporated to afford 7.5 g of a purple oil.
- the reaction was then heated to 80°C for 30 min and then partitioned between ethyl acetate (50 mL) and water (20 mL) and separated. The aqueous layer was further extracted with EtOAc (2 x 30 mL). The combined organic layers were then washed with water (25 mL), brine, dried over Na 2 SO 4 , and the solvent was removed under reduced pressure. This was then heated to 60°C in a 1 N HCl/MeOH solution overnight with stirring. The reaction mixture was cooled and concentrated to dryness.
- 6-Chloro-4-piperidin-4-yl-4H-benzo[1,4]oxazin-3-one (252 mg, 0.66 mmol) and 5-methanesulfonyl-1-oxiranylmethyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (209 mg, 0.52 mmol) were set stirring in EtOH (10 mL) containing Et 3 N (115 ⁇ L, 0.83 mmol) at 70°C. After 2 days the mixture was cooled, evaporated, brought up in EtOAc and washed with saturated NaHCO 3 .
- 1,1'-Carbonyldiimidazole (0.51 g, 3.15 mmol) was added to a solution of 4-(2-aminomethyl-4-chloro-phenylamino)-piperidine-1-carboxylic acid tert-butyl ester (0.79 g, 2.25 mmol) in CH 3 CN (10 mL) over 3 h with stirring at 50°C. The reaction mixture was then cooled to room temperature and stirred for additional 2 h. The reaction mixture was dissolved in CH 2 Cl 2 (100 mL), washed with water (2 x 10 mL), brine (1 x 10 mL). The organic layer was dried over Na 2 SO 4 and concentrated.
- Dess-Martin periodinane (1.43 g, 3.36 mmol) was added portion wise to a stirred solution of 1-(3-hydroxy-propyl)-3-(4-trifluoromethyl-phenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (1.30 g, 3.05 mmol) in CH 2 Cl 2 (15 mL) at 0 °C under N 2 . Then the reaction was stirred at 0 °C for 15 min and allowed to warm to room temperature.
- PpTs (271 mg, 1.1 mmol) and (R)-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propane-1,2-diol (317 mg, 0.756 mmol) were combined in trimethylorthoacetate (30 mL). The mixture was stirred for 18 h then diluted with EtOAc (125 mL), washed with saturated NaHCO 3 (2 x 50 mL), brine (50 mL), dried over Na 2 SO 4 and concentrated.
- CatS Recombinant human cathepsin S
- CatS Recombinant human cathepsin S
- 10-L yielded ⁇ 700 mg of CatS and N-terminal sequencing confirmed identity.
- the assay is run in 100 mM sodium acetate pH 5.0 containing 1 mM DTT and 100 mM NaCl.
- the substrate for the assay is (Aedens)EKARVLAEAA(Dabcyl)K-amide
- the K m for the substrate is around 5 ⁇ M but the presence of substrate inhibition makes kinetic analysis difficult.
- the assay rate is linear over the range of 1-8 ng CatS in 100 ⁇ l reaction.
- the production of product is linear and yields -7-fold signal after 20 min with only 20% loss of substrate.
- Primary assays are run by quenching the reaction after 20 min with 0.1 % SDS and then measuring the fluorescence. For other assays, measurements are taken every min for 20 min. The rate is calculated from the slope of the increase and the percent inhibition is calculated from this (See Tables 1 and 2 below).
- EXAMPLE lC 50 ( ⁇ M) 1 0.73 2 0.07 3 0.28 4 0.19 5 1.16 6 0.19 7 0.26 8 0.04 9 0.10 10 0.09 11 0.03 12 0.62 13 0.37 14 0.29 15 0.23 16 0.30 17 1.30 18 0.25 19 0.02 20 0.01 21 0.02 22 0.03 23 0.08 24 0.03 25 0.23 26 0.18 27 0.09 28 0.89 29 0.78 30 0.04 31 0.07 Table 2 EXAMPLE IC 50 ( ⁇ M) 32 0.06 33 0.01 34 0.02 35 0.03 36 0.04 37 0.05 38 0.02 39 0.04 40 0.04 41 0.03 42 0.08 43 0.02 44 0.03 45 0.02 46 0.03 47 0.04 48 0.02 49 0.02 50 0.02 51 0.02 52 0.13 53 0.05
- the following assay demonstrates that cathepsin S inhibitors block the response of human T cells to crude allergen extracts.
- Glycerinated crude allergen extracts of house dust mites Dermataphagoides pteronyssinus, Dermataphagoides farinae
- ragweed Ambrosia trifida (giant), Ambrosia artemisiifolia (short)] were purchased from Hollister-Stier Laboratories (Minneapolis, MN).
- PBMC Human peripheral blood mononuclear cells
- PBS phosphate buffered saline
- PBMC peripheral blood mononuclear cells
- HDM house dust mites
- Dermatophagoides Dermatophagoides with Dermatophagoides pteronyssinus (Der p) and D. farinae (Der f) being the two major species present in varying proportions in most countries.
- the major clinical manifestations are asthma and perennial rhinitis.
- This system is very similar to an in vivo situation.
- the allergic subject would be exposed to a crude mixture of allergens that would lead to the proliferation of T cells and an allergic response.
- the observation of inhibition of CD4 T cell activation by a cathepsin S inhibitor shows that such inhibitors can be effective in treating a generalized population of patients allergic to house dust mites.
- This system is very similar to an in vivo situation.
- the allergic subject would be exposed to a crude mixture of allergens that would lead to the proliferation of T cells and an allergic response.
- the observation of inhibition of CD4 T cell activation by a cathepsin S inhibitor shows that such inhibitors can be effective in treating a generalized population of patients allergic to ragweed.
- the effect of in vivo administration of cathepsin S inhibitors, in a clinical trial setting, can be monitored by measuring accumulation of an intermediate degradation product of invariant chain (li), i.e. the p10li fragment, in blood of dosed subjects.
- li invariant chain
- a cathepsin inhibitor for a certain period of time, for example, between 0.01 and 50 mg/kg/day, to result in a blood concentration of between 1 nM-10 ⁇ M, for 16-30 h
- blood is drawn and white blood cells are purified, e.g. either by lysis of red blood cells or by a Ficoll-Hypaque gradient centrifugation.
- li and its intermediate degradation products including the p10li, can be detected using a mouse mAb against li, e.g. Pin 1.1, or rabbit polyclonal antibodies specific for the C-terminus of the p10li fragment or against the entire p10li fragment.
- ELISA assay For ELISA assay, a pair of antibodies against li, including Pin1.1, and a rabbit polyclonal antibody or a mouse monoclonal antibody specific for p10li, can be used. The same assay can also be applied to monitor the effect of cathepsin S inhibitors in vivo in animal studies, for example in monkeys, dogs, pigs, rabbits, guinea pigs, and rodents.
- PBMC from human blood were incubated with the cathepsin S inhibitor, LHVS (morpholinurea-leucine-homo-phenylalanine-vinylsulfonephenyl, also referred to as 4-morpholinecarboxamide, N-[(1S)-3-methyl-1-[[[(1S,2E)-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propenyl]amino]carbonyl]butyl]-.
- LHVS morpholinurea-leucine-homo-phenylalanine-vinylsulfonephenyl, also referred to as 4-morpholinecarboxamide, N-[(1S)-3-methyl-1-[[[(1S,2E)-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propenyl]amino]carbonyl]butyl]-.
- the immediate weal and flare response is not mediated by a T cell response and is not expected to be influenced by cathepsin S inhibitors, while the late phase induration (noticeable at 6 hours, more pronounced at 24 hours) is characterized by activation and infiltration of CD4 T cells (as well as of eosinophils) and should be inhibited by administration of inhibitors of cathepsin S.
- the skin biopsies are used to determine the cellular composition in the induration, and cathepsin S treated subjects are expected to have fewer activated CD4 T cells present than placebo-treated subjects.
- prednisone and cyclosporine A will be used as controls for the experiment. Prednisone will inhibit both the immediate and the late phase responses, while cyclosporin A will inhibit only the late phase response.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23040700P | 2000-09-06 | 2000-09-06 | |
US230407P | 2000-09-06 | ||
US927324 | 2001-08-10 | ||
US09/927,324 US6953793B2 (en) | 2000-08-14 | 2001-08-10 | Substituted pyrazoles |
PCT/US2001/027429 WO2002020011A2 (en) | 2000-09-06 | 2001-09-05 | A method for treating allergies using substituted pyrazoles |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1315490A2 EP1315490A2 (en) | 2003-06-04 |
EP1315490B1 true EP1315490B1 (en) | 2008-11-12 |
Family
ID=26924203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01968461A Expired - Lifetime EP1315490B1 (en) | 2000-09-06 | 2001-09-05 | A method for treating allergies using substituted pyrazoles |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1315490B1 (hu) |
JP (1) | JP2004531456A (hu) |
KR (1) | KR100818056B1 (hu) |
CN (1) | CN1212839C (hu) |
AT (1) | ATE413878T1 (hu) |
AU (2) | AU2001288706B2 (hu) |
BR (1) | BR0114054A (hu) |
CA (1) | CA2421493A1 (hu) |
CZ (1) | CZ2003635A3 (hu) |
DE (1) | DE60136546D1 (hu) |
HK (1) | HK1053794A1 (hu) |
HU (1) | HUP0302475A2 (hu) |
MX (1) | MXPA03001963A (hu) |
NZ (1) | NZ524681A (hu) |
PL (1) | PL365606A1 (hu) |
WO (1) | WO2002020011A2 (hu) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1598338T1 (sl) | 2001-04-18 | 2009-06-30 | Euro Celtique Sa | Derivati 1-(4-piperidinil)-1,3-dihidro-2H-indol-2-ona in sorodne spojine kot analogi nociceptina in ligandi ORL1 za zdravljenje bolečine |
NZ528978A (en) | 2001-04-18 | 2004-06-25 | Euro Celtique S | Spiropyrazole compounds |
AU2002338424B2 (en) | 2001-04-18 | 2005-04-21 | Euro-Celtique S.A. | Benzimidazolone compounds |
CA2444108C (en) * | 2001-04-18 | 2012-07-24 | Euro-Celtique, S.A. | Nociceptin analogs |
DE60229736D1 (de) | 2001-04-18 | 2008-12-18 | Euro Celtique Sa | Spiroinden- und spiroindan-verbindungen |
US20030166037A1 (en) * | 2002-01-16 | 2003-09-04 | Fourie Anne M. | Aggrecanase-1 and -2 peptide substrates and methods |
SG146683A1 (en) * | 2003-09-17 | 2008-10-30 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as serotonin receptor modulators |
US20080200454A1 (en) * | 2007-02-15 | 2008-08-21 | Ameriks Michael K | Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
EP2308866A1 (de) * | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
KR20110069692A (ko) * | 2009-12-17 | 2011-06-23 | 엘지전자 주식회사 | 광대역 이동 통신 시스템에서 긴급 서비스 정보 제공 장치 및 방법 |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
EP2920183B1 (en) | 2012-11-14 | 2017-03-08 | Glaxosmithkline LLC | Thieno[3,2-c]pyridin-4(5h)-ones as bet inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
PT2986610T (pt) | 2013-04-19 | 2018-03-09 | Incyte Holdings Corp | Heterociclos bicíclicos como inibidores de fgfr |
JP6826527B2 (ja) * | 2014-09-18 | 2021-02-03 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | カテプシンs阻害をモニタリングするための方法 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
ES2899906T3 (es) | 2015-07-06 | 2022-03-15 | Alkermes Inc | Inhibidores bicíclicos de histona desacetilasa |
US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
BR112019014235A2 (pt) | 2017-01-11 | 2020-03-17 | Rodin Therapeutics, Inc. | Inibidores bicíclicos de histona desacetilase |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
LT3664802T (lt) | 2017-08-07 | 2022-06-27 | Alkermes, Inc. | Bicikliniai histonų deacetilazės inhibitoriai |
BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
PE20210920A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Formas solidas de un inhibidor de fgfr y procesos para prepararlas |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0615542B2 (ja) * | 1986-07-22 | 1994-03-02 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
FR2705962B1 (fr) * | 1993-06-03 | 1995-07-13 | Rhone Poulenc Agrochimie | Arylpyrazoles fongicides. |
US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
WO1998056785A1 (fr) * | 1997-06-12 | 1998-12-17 | Sumitomo Pharmaceuticals Co., Ltd. | Derives de pyrazole |
DE60135130D1 (de) * | 2000-09-06 | 2008-09-11 | Ortho Mcneil Pharm Inc | Verwendung von substituierten pyrazolen zur behandlung von allergien |
-
2001
- 2001-09-05 PL PL01365606A patent/PL365606A1/xx not_active Application Discontinuation
- 2001-09-05 CN CNB018185010A patent/CN1212839C/zh not_active Expired - Fee Related
- 2001-09-05 BR BR0114054-0A patent/BR0114054A/pt not_active Application Discontinuation
- 2001-09-05 DE DE60136546T patent/DE60136546D1/de not_active Expired - Fee Related
- 2001-09-05 KR KR1020037003357A patent/KR100818056B1/ko not_active IP Right Cessation
- 2001-09-05 AU AU2001288706A patent/AU2001288706B2/en not_active Ceased
- 2001-09-05 AT AT01968461T patent/ATE413878T1/de not_active IP Right Cessation
- 2001-09-05 AU AU8870601A patent/AU8870601A/xx active Pending
- 2001-09-05 CA CA002421493A patent/CA2421493A1/en not_active Abandoned
- 2001-09-05 CZ CZ2003635A patent/CZ2003635A3/cs unknown
- 2001-09-05 HU HU0302475A patent/HUP0302475A2/hu unknown
- 2001-09-05 MX MXPA03001963A patent/MXPA03001963A/es active IP Right Grant
- 2001-09-05 NZ NZ524681A patent/NZ524681A/en unknown
- 2001-09-05 EP EP01968461A patent/EP1315490B1/en not_active Expired - Lifetime
- 2001-09-05 JP JP2002524495A patent/JP2004531456A/ja active Pending
- 2001-09-05 WO PCT/US2001/027429 patent/WO2002020011A2/en active IP Right Grant
-
2003
- 2003-08-22 HK HK03106038.8A patent/HK1053794A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU8870601A (en) | 2002-03-22 |
NZ524681A (en) | 2005-09-30 |
MXPA03001963A (es) | 2004-03-18 |
KR20040007393A (ko) | 2004-01-24 |
WO2002020011A2 (en) | 2002-03-14 |
WO2002020011A3 (en) | 2002-06-13 |
CN1473043A (zh) | 2004-02-04 |
CZ2003635A3 (cs) | 2004-12-15 |
CN1212839C (zh) | 2005-08-03 |
CA2421493A1 (en) | 2002-03-14 |
BR0114054A (pt) | 2003-07-01 |
PL365606A1 (en) | 2005-01-10 |
AU2001288706B2 (en) | 2006-01-19 |
KR100818056B1 (ko) | 2008-03-31 |
HUP0302475A2 (hu) | 2003-11-28 |
JP2004531456A (ja) | 2004-10-14 |
HK1053794A1 (en) | 2003-11-07 |
ATE413878T1 (de) | 2008-11-15 |
DE60136546D1 (de) | 2008-12-24 |
EP1315490A2 (en) | 2003-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1315490B1 (en) | A method for treating allergies using substituted pyrazoles | |
US6583155B2 (en) | Method for treating allergies using substituted pyrazoles | |
EP1309593B1 (en) | Substituted pyrazoles | |
EP1309592B9 (en) | Substituted pyrazoles | |
AU2001288706A1 (en) | A method for treating allergies using substituted pyrazoles | |
US20070117785A1 (en) | Substituted pyrazoles and methods of treatment with substituted pyrazoles | |
AU2001286454A1 (en) | Substituted pyrazoles | |
US20020055497A1 (en) | Method for treating allergies using substituted pyrazoles | |
EP1315492B1 (en) | Use of substituted pyrazoles for the treatment of allergies | |
AU2001288731A1 (en) | A method for treating allergies using substituted pyrazoles | |
RU2259202C2 (ru) | Способ лечения аллергии с использованием замещенных пиразолов | |
EP1315491B1 (en) | Use of substituted pyrazoles for the manufacture of a medicament for the treatment of allergies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030313 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MEDUNA, STEVEN, P. Inventor name: WEI, JIANMEI Inventor name: THURMOND, ROBIN, L. Inventor name: SUN, SIQUAN Inventor name: PIO, BARBARA, A. Inventor name: TAYS, KEVIN, L. Inventor name: EDWARDS, JAMES, P. Inventor name: BUTLER, CHRISTOPHER, R. Inventor name: CAI, HUI Inventor name: GRICE, CHERYL, A. Inventor name: KARLSSON, LARS Inventor name: KHATUYA, HARIPADA Inventor name: GU, YIN Inventor name: SEHON, CLARK, A. Inventor name: GUSTIN, DARIN, J. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KHATUYA, HARIPADA Inventor name: GUSTIN, DARIN, J. Inventor name: WEI, JIANMEI Inventor name: KARLSSON, LARS Inventor name: PIO, BARBARA, A. Inventor name: MEDUNA, STEVEN, P. Inventor name: THURMOND, ROBIN, L. Inventor name: TAYS, KEVIN, L. Inventor name: GU, YIN Inventor name: CAI, HUI Inventor name: GRICE, CHERYL, A. Inventor name: EDWARDS, JAMES, P. Inventor name: SEHON, CLARK, A. Inventor name: BUTLER, CHRISTOPHER, R. Inventor name: SUN, SIQUAN |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/536 20060101ALI20080508BHEP Ipc: A61K 31/4162 20060101ALI20080508BHEP Ipc: A61K 31/44 20060101ALI20080508BHEP Ipc: A61P 37/08 20060101ALI20080508BHEP Ipc: A61K 31/437 20060101AFI20080508BHEP |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60136546 Country of ref document: DE Date of ref document: 20081224 Kind code of ref document: P |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. |
|
NLT2 | Nl: modifications (of names), taken from the european patent patent bulletin |
Owner name: ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. Effective date: 20090121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081112 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090223 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081112 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081112 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1053794 Country of ref document: HK |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081112 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090413 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090212 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20090813 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20090827 Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20090905 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20100531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090930 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090905 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100401 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090930 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090213 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090905 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100930 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090905 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081112 |